0001213900-26-034835 | 10-K | XBRL Viewer | Oramed Pharmaceuticals INC

Print Document

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Oct. 20, 2025	Mar. 18, 2024	Dec. 31, 2025	Dec. 31, 2024	Oct. 30, 2025	May 21, 2025	Oct. 30, 2024	Jun. 30, 2024
Stockholders’ Equity [Line Items]
Warrants exercisable outstanding shares (in Shares)			20,000	20,000	100,000
Exercise price per share (in Dollars per share)			$ 4.13	$ 4.13
Repurchased, shares (in Shares)	1,155,367		899,609	1,036,976
Amount of repurchased shares			$ 2,155	$ 2,494
Excise tax	$ 8		$ 6	$ 10
Average price of per share (in Dollars per share)			$ 2.39	$ 2.4
Purchase price of per share (in Dollars per share)	$ 2.23
Cash dividend of per share (in Dollars per share)			0.25
Warrant [Member]
Stockholders’ Equity [Line Items]
Cash dividend of per share (in Dollars per share)			0.25
RSU [Member]
Stockholders’ Equity [Line Items]
Cash dividend of per share (in Dollars per share)			$ 0.25
Buyback program [Member]
Stockholders’ Equity [Line Items]
Repurchase of common stock amount						$ 20,000		$ 20,000
Repurchased, shares (in Shares)			1,936,585
Amount of repurchased shares	$ 2,584
Stock Block ATM Agreement [Member]
Stockholders’ Equity [Line Items]
Offering price		$ 75,000
Commission percentage		3.00%
Common Stock [Member]
Stockholders’ Equity [Line Items]
Warrants exercisable outstanding shares (in Shares)							185,715
Amount of repurchased shares			$ 4,649
Cash dividend of per share (in Dollars per share)			$ 0.25
Dividend			$ 10,870

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Related Parties

Balances with related parties:

	December 31,
	2025		2024
Accounts payable and accrued expenses - Shnida	$	380	$	175
Accounts payable and accrued expenses - Miriam Kidron		272		154
Total payable to related parties	$	652	$	329

Expenses to related parties:

	Year ended December 31,
	2025		2024
KNRY	$	562	$	563
Miriam Kidron (Chief Scientific Officer)		150		-
Shnida		768		514
Nadav Kidron (President and Chief Executive Officer)		232		297
Total expenses to related parties	$	1,712	$	1,374

Significant Accounting Policies

12 Months Ended

Dec. 31, 2025

Significant Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:

General

Oramed Pharmaceuticals Inc. (collectively with its subsidiaries, the “Company,” unless the context indicates otherwise), a Delaware corporation, was incorporated on April 12, 2002.

On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the “Subsidiary”), which is engaged in research and development.

On March 18, 2021, the Company entered into a license agreement with Oravax Medical Inc. (“Oravax”) and holds 63% of the issued and outstanding share capital of Oravax, on a fully diluted basis, as of the date of issuance. Consequently, Oramed consolidates Oravax in its consolidated financial statements since that time.

As of December 31, 2025, Oravax ceased its operations. As a result, the Company waved the loan owed by Oravax to the Company (“waver of the loan”). In connection with the waiver of the loan, which effectively constituted a benefit to the non-controlling interest, the Company recognized the impact as an adjustment to non-controlling interest balance, with a corresponding adjustment to additional paid-in capital.

On July 1, 2024, the Company incorporated a wholly-owned subsidiary in Nevada, Oramed NewCo, Inc. (“OraTech”), which was initially intended to serve as the joint venture entity with Hefei Tianhui Biotech Co., Ltd. (“HTIT”) (see below). Following the termination of the JV Agreement with HTIT, the Company intends to use OraTech as a corporate vehicle for the transaction with Lifeward (for additional information see note 21).

Joint venture with HTIT

On February 7, 2025, the Company and HTIT entered into a Joint Venture Agreement (the “JV Agreement”), amending the Initial JV Agreement. The joint venture (“JV”) was formed with the purpose of advancing the development and commercialization of oral insulin, combining the Company’s proprietary technology and funding with HTIT’s manufacturing capabilities. Through this partnership, the JV was expected to have the technology, resources, and production capacity to bring oral insulin to market.

The initial closing of the JV Agreement, initially set on April 30, 2025, and was subsequently extended. However, HTIT was unable to satisfy the closing conditions under the JV Agreement and the supplemental agreement. On October 23, 2025, the Company provided notice to HTIT to terminate the JV Agreement and the supplemental agreement.

Investment in Alpha Tau Medical Ltd.

In April 2025, the Subsidiary acquired approximately 17% of the outstanding ordinary shares of Alpha Tau Medical Ltd. (“Alpha Tau”) (Nasdaq: DRTS) for an aggregate purchase price of $36,900. Concurrently, the Subsidiary and Alpha Tau also entered into a services arrangement (“Service Agreement”). Further details are provided in note 8.

Basis of presentation

The consolidated financial statements included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”).

Use of estimates in the preparation of financial statements

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported revenues and expenses during the reporting periods. Actual results could differ from those estimates.

As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to the investments at fair value (for further details, see note 4).

Functional currency

The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Therefore, the functional currency of the Company and its subsidiaries is the dollar.

Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions – exchange rates at transaction dates or average rates and (2) for other items (derived from non-monetary balance sheet items such as depreciation) – historical exchange rates. The resulting transaction gains or losses are carried to financial income or expenses, as appropriate.

Repurchase and retirement of common stock

The Company debited the common stock account by the par value of the shares retired and allocated the excess of the repurchase price over the par value of the shares to additional paid in capital.

Principles of consolidation

The consolidated financial statements include the accounts of the Company and its subsidiaries. All inter-company transactions and balances have been eliminated in consolidation.

Cash equivalents

The Company considers all short-term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.

Fair value measurement:

The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:

	Level 1:	Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

	Level 2:	Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

	Level 3:	Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:

	December 31, 2025
	Level 1		Level 2		Level 3		Fair Value
Assets:
Marketable Securities
DNA		540		-		-		540
Entera		227		-		-		227
Nano		8,371		-		-		8,371
Pelthos		4,650		-		-		4,650
Investment in Alpha Tau’s shares (see note 8)		71,623		-		-		71,623
Loan to an equity method investee (see note 6)		-		-		553		553
Warrants Note B (see note 4)		-		-		850		850
Tranche A Note (see note 4)		-		-		23,063		23,063
Tranche B Note (see note 4)		-		-		11,473		11,473
Royalty Purchase Agreement (see note 4)		-		-		2,209		2,209
Profit Sharing Loan Agreement (see note 4 (e))		-		-		1,890		1,890
Loan agreement measured in fair value (see note 7)		-		-		27,943		27,943
Investment in Alpha Tau’s warrants (see note 8)		-		-		6,242		6,242
Convertible note (see note 9)		-		-		4,636		4,636
	$	85,411	$	-	$	78,859	$	164,270

	December 31, 2024
	Level 1		Level 2		Level 3		Fair Value
Assets:
Marketable Securities
DNA		424		-		-		424
Entera		248		-		-		248
Scilex		2,769		-		-		2,769
Subsequent Penny Warrants (see note 4)		-		2,772		-		2,772
Warrants Note B (see note 4)		-		-		548		548
Tranche A Note (see note 4)		-		-		13,714		13,714
Tranche B Note (see note 4)		-		-		15,798		15,798
Royalty Purchase Agreement (see note 4)		-		-		1,976		1,976
Profit Sharing Loan Agreement (see note 4)		-		-		1,367		1,367
	$	3,441	$	2,772	$	33,403	$	39,616

As of December 31, 2025, and December 31, 2024, the carrying amounts of cash equivalents, short-term deposits, and accounts payable approximate their fair values due to the short-term maturities of these instruments.

The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.

Marketable securities

The Company measured the investments in equity securities of IC Hotels (“DNA”), Entera Bio Ltd. (“Entera”), Nano Dimension Ltd (“Nano”) and Pelthos Therapeutics Inc. (“Pelthos”) at fair value, with changes in fair value recognized in earnings. The Company intends to exercise the investments in DNA, Entera and Pelthos during 2026 and has classified these marketable securities as short-term accordingly.

Other non-marketable equity securities

The Company also invested in non-marketable equity securities through an investment in a privately held company. This equity investment does not have a readily determinable fair value. The investment is measured under the measurement alternative in Accounting Standards Codification (“ASC”) 321 “Investments – Equity Securities” to the extent such an investment is not subject to consolidation or the equity method. Under the measurement alternative, this equity investment is carried at cost, less any impairment, adjusted for changes resulting from observable price changes in transactions for an identical or similar investment of the same issuer. The investment would be impaired in accordance with the provisions of ASC 820 “Fair Value Measurement” if, based on a qualitative assessment of impairment indicators, the fair value of the investment is less than its carrying amount. If considered impaired, the difference between the carrying amount and fair value would be recorded in the consolidated statement of comprehensive income (loss). see note 10.

Investments measured at fair value

The Company invested in the Tranche A Note (as defined in note 4), Tranche B Note (as defined in note 4) (collectively the “Notes”), Loan to an equity method investee, Convertible note, Investment in Alpha Tau and Royalty Purchase Agreement issued by Scilex, for which it has elected the fair value option. Under the Fair Value Option Subsections of ASC Subtopic 825-10, Financial Instruments – Overall, the Company has the irrevocable option to report financial assets at fair value on an instrument-by-instrument basis.

Scilex also issued to the Company the Note A Transferred Warrants and Note B Warrants (as defined in note 4) that meet the definition of a derivative under ASC 815 “Derivatives and Hedging”. Therefore, such warrants will be measured at fair value initially and at every reporting period.

The Company entered into a loan agreement to finance real estate projects. The Company decided to designate the Profit Sharing Loan Agreement (as define in note 4) and the Hapisga (as define in note 7) as a whole under the Fair-Value option in accordance with ASC Topic 825 “Financial Instruments”.

Changes in the fair value are recorded under financial income (expenses), net.

Concentration of credit risks

Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents, short and long-term deposits, which are deposited in major financial institutions, Profit Sharing Loan Agreement, Hapisga, Royalty Purchase Agreement, convertible note and the Notes.

The Company is of the opinion that the credit risk in respect of these balances is remote, except for the Profit Sharing Loan Agreement, Hapisga, Royalty Purchase Agreement, convertible note and the Notes for which the Company is of the opinion there is a credit risk, which is reflected in its fair value measurement (for further details, see note 4).

Income taxes

Deferred taxes

Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

The Company maintains a full valuation allowance against the deferred tax assets of certain entities, as management has determined that it is not more likely than not that such deferred tax assets will be realized. For further details see note 18.

Taxes that would apply in the event of disposal of investments in the Israeli subsidiary have not been taken into account in computing deferred taxes, as it is the Company’s intention to hold this investment, not to realize it.

Uncertainty in income tax

The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within 12 months from the balance sheet date. The Company’s policy is to include interest and penalties related to unrecognized tax benefits within income tax expenses.

Revenue recognition

HTIT

On November 30, 2015, the Company entered into a Technology License Agreement, with HTIT and on December 21, 2015, the parties entered into an Amended and Restated Technology License Agreement that was further amended by the parties on June 3, 2016 and July 24, 2016 (the “HTIT License Agreement”).

As of December 31, 2024, an aggregate amount of $22,382 was allocated to the HTIT License Agreement, all of which were received through December 31, 2024. Through December 31, 2024, the Company recognized revenue associated with this agreement in the aggregate amount of $20,382, and deferred the remaining amount of $2,000, which was presented as long-term deferred revenues on the consolidated balance sheet as of December 31, 2024.

In the year ended December 31, 2025, the Company recognized revenue associated with the HTIT License Agreement in an amount of $2,000 following HTIT’s waiver of any claims and demands against the Company, which was signed in connection with the JV Agreement. As of December 31, 2025, all revenue associated with the contract was fully recognized.

Other income

The Company recognizes income from its Service Agreement with Alpha Tau for investor relations and public relations on a straight-line basis. Under the Service Agreement, the Company received non-cash consideration of Alpha Tau Warrants (as defined below) to purchase up to 3,237,000 shares, measured at their issuance date fair value of $2,727 and entitled to receive six semi-annual payments of $500, totaling $3,000. The income is presented under the “Other income, net” line item (net of related expenses), since the Company does not view investor relations services to be output of its ordinary activities. In addition, changes in the fair value of the Alpha Tau Warrants are presented under “Financial Income (loss), net”.

During 2025, the Company issued invoices in an aggregate amount of $997. Of this amount, $553 was recognized as income and recorded under “Other income, net,” while the remaining $444 was deferred and presented under “Deferred income”.

In addition, the Company recorded an income of $549 related to the straight-line recognition of the Alpha Tau Warrants under “Other income, net”. For further details, see Note 8.

Research and development

Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, stock-based compensation, employee benefits, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company’s clinical trials, clinical trial expenses and the full cost of manufacturing drug for use in research and preclinical development. All costs associated with research and development are expensed as incurred.

Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as Clinical Research Organizations (“CROs”), independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical trials. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately.

Stock-based compensation

Equity awards granted to employees are accounted for using the grant date fair value method. The grant date fair value is determined as follows: for stock options with an exercise price and only service conditions, using the Black Scholes pricing model; for stock options and performance stock units (“PSUs”) with market conditions using a Monte Carlo model; and for restricted stock units (“RSUs”) with service conditions and PSUs with performance conditions, based on the grant date share price.

The fair value of share based payment awards is recognized as an expense over the requisite service period. The expected term is the length of time until the expected dates of exercising the award and is estimated using the simplified method due to insufficient specific historical information of employees’ exercise behavior, unless the award includes a market condition, in which case the contractual term is used. The volatility is based on a historical volatility, by statistical analysis of the weekly share price for past periods. The Company elected to recognize compensation cost for awards granted to employees that have a graded vesting schedule using the accelerated method based on the multiple-option award approach. For awards with market conditions, compensation expense is not reversed if the market conditions are not satisfied.

If a market condition associated with PSUs is satisfied earlier than originally expected, any remaining unrecognized compensation cost related to such awards is recognized immediately.

The Company elects to account for forfeitures as they occur.

Income (loss) per share of common stock

Basic income (loss) per common stock is computed by dividing the net income (loss) attributable to stockholders for the period by the weighted average number of shares of common stock outstanding for each period, including vested restricted stock units (“RSUs”). The net income available to common stockholders is reduced by dividend equivalents declared on unvested RSUs, as such awards are not considered participating securities and are excluded from the basic share count.

For the diluted income (loss) per common stock calculation for the year ended December 31, 2025, dividend equivalents attributable to unvested RSUs were added back to the numerator only when the RSUs referred to are dilutive. The weighted average number of shares outstanding during the period is adjusted for the potential dilution that could occur in connection with employee share-based payment, using the treasury stock method. As the Company had a net loss for the year ended December 31, 2024, all potentially dilutive common stock were considered antidilutive and therefore excluded from the calculation of diluted weighted average shares outstanding. For further details, see Note 16.

Investment in Alpha Tau

The Company holds an investment in Alpha Tau granting it significant influence over the investee. In determining whether the Company has significant influence, the Company considered not only whether its ownership is equal to or greater than 20%, but less than or equal to 50%, but also whether it has a board seat and whether it participates in the policy-making process of the investee, among other criteria.

Investments granting significant influence are generally accounted for under the equity method. For the investment in Alpha Tau, the Company has elected the fair value option under ASC 825-10. The fair value option has been elected as the Company believes it best reflects the underlying economics of the investment in Alpha Tau. As a result, the Company recognizes the change in the fair value in “Financial income (loss), net”.

Summarized financial information for Alpha Tau, as determined in accordance with Rule 8-03(b)(3) of Regulation S-X is included in note 8.

Leases

The Company leases real estate and cars for use in its operations, which are classified as operating leases. In addition to rent, the leases may require the Company to pay directly for fees, insurance, maintenance and other operating expenses.

The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right of use assets and operating lease liabilities in the consolidated balance sheets. Right of use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease

ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments. Lease expenses are recognized on a straight-line basis over the lease term.

The Company elected the practical expedient to not separate lease and non-lease components for all of its leases.

Lease terms will include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease.

The Company’s lease agreements have remaining lease terms ranging from 1 year to 5 years. Some of these agreements include options to extend the leases for up to an additional 5 years and some include options to terminate the leases immediately. For further details, see Note 13.

New accounting pronouncements

Recently adopted accounting pronouncements

In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The Company adopted this standard on a prospective basis. For further details, see note 18.

Recently issued accounting pronouncements, not yet adopted

In November 2024, the FASB issued ASU 2024-03 “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses”, which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement as well as disclosures about selling expenses. ASU 2024-03 is effective for years beginning after December 15, 2026, and interim periods within years beginning after December 15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

In July 2025, the FASB issued ASU 2025-05 “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets”. The ASU introduces a practical expedient for all entities when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under ASC 606. Under the practical expedient, when developing reasonable and supportable forecast as part of estimating expected credit losses, an entity may assume that current conditions as of the balance sheet date do not change for the remaining life of the asset. The ASU is effective for annual reporting periods beginning after December 15, 2025 and interim reporting within those annual reporting periods. Early adoption is permitted in both interim and annual reporting periods. The Company is evaluating the impact of ASU 2025-05 on its consolidated financial statements if it elects to apply the practical expedient.

In September 2025, the FASB issued ASU No. 2025-07 (“ASU 2025-07”), Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606). The guidance refines the scope of Topic 815 by clarifying which contracts are subject to derivative accounting and expand the scope exception for certain contracts not traded on an exchange to include contracts for which settlement is based on operations or activities specific to one of the parties to the contract. The guidance also provides clarification under Topic 606 for share-based payments from a customer in a revenue contract. The amendments in ASU 2025-07 are effective for annual periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The amendments may be applied prospectively or on a modified retrospective basis. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 64,016	$ (19,103)
Depreciation	121	193
Exchange differences and interest on deposits	830	(2,700)
Changes in fair value of investments	(86,096)	7,413
Stock-based compensation	5,992	4,053
Gain on amounts funded in respect of employee rights upon retirement	(12)	(5)
Change in accrued interest on short-term borrowings		(1,463)
Prepaid expenses and other current assets	(998)	(356)
Accounts payable, accrued expenses and related parties	1,130	3,525
Net changes in operating lease	117	43
Deferred revenues	(2,000)
Deferred income	(105)
Liability for employee rights upon retirement	9	2
Deferred tax liabilities	7,911
Other liabilities	(60)	(14)
Total net cash used in operating activities	(9,145)	(8,412)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(9)	(18)
Purchase of short-term deposits	(10,948)	(54,450)
Purchase of marketable securities	(9,846)
Investments at fair value	(64,712)	(1,307)
Purchase of convertible note	(3,000)
Proceeds from redemption of short-term deposits	54,450	97,152
Exercise of Closing Penny Warrants and Subsequent Penny Warrants		(65)
Proceeds from loan to an equity method investee	6,251
Loan to investment in equity method	(7,000)
Real estate investment	(1,924)
Equity method investee	(250)
Proceeds from long-term deposits		5
Proceeds from marketable securities	2,865
Proceeds from long-term investments and marketable securities	39,566	64,500
Total net cash provided by investing activities	5,443	105,817
CASH FLOWS FROM FINANCING ACTIVITIES:
Repurchase and retirement of common stock	(4,741)	(2,484)
Loans repaid		(49,550)
Tax withholdings related to stock-based compensation settlements		(2)
Total net cash used in financing activities	(4,741)	(52,036)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	(30)	(4)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(8,473)	45,365
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	54,420	9,055
CASH AND CASH EQUIVALENTS AT END OF YEAR	45,947	54,420
(A) SUPPLEMENTARY DISCLOSURE ON CASH FLOWS:
Interest paid		2,316
Interest received	4,626	7,376
(B) SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES:
2024 Refinancing Tranche A		(21,575)
2024 Refinancing Tranche B		25,000
Excise tax for repurchase and retirement of common stock	(15)	(10)
Recognition of operating lease right-of-use assets and liabilities	600	58
Waiver of loan granted to subsidiary	952
Derecognition of right-of-use asset		(26)
Derecognition of lease liability		23
Purchases of marketable securities not yet settled	254
Dividends declared but not yet paid in cash	10,870
Warrants received from Alpha Tau	$ 2,727

Taxes on Income - Schedule of Deferred Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 30, 2025	Dec. 31, 2024	Dec. 30, 2024
Schedule of Deferred Income Taxes [Absract]
Net operating loss carryforward	$ 27,306		$ 26,797
Research and development expenses	1,005		1,220
Revaluation of investments	(7,973)		5,608
Other temporary differences	134		2,495
Less - valuation allowance	(28,383)	$ (36,120)	(36,120)	$ (28,473)
Net deferred tax liability	$ (7,911)

Investment in Associate at Fair Value - Schedule of Valuation of the Warrants (Details) - Warrant [Member]	Dec. 31, 2025	Jun. 23, 2025
Share Price [Member]
Schedule of Valuation of the Warrants [Line Items]
Warrants Measurement Input	4.95	2.985
Exercise Price [Member] \| Minimum [Member]
Schedule of Valuation of the Warrants [Line Items]
Warrants Measurement Input	3.47	3.47
Exercise Price [Member] \| Maximum [Member]
Schedule of Valuation of the Warrants [Line Items]
Warrants Measurement Input	3.9	3.9
Expected Term [Member]
Schedule of Valuation of the Warrants [Line Items]
Warrants Measurement Input	1.81	2.35
Volatility [Member]
Schedule of Valuation of the Warrants [Line Items]
Warrants Measurement Input	49.04	55.61
Risk Free Rate [Member]
Schedule of Valuation of the Warrants [Line Items]
Warrants Measurement Input	3.47	3.89
Dividend Rate [Member]
Schedule of Valuation of the Warrants [Line Items]
Warrants Measurement Input	0	0

Commitments (Details) ₪ in Thousands, $ in Thousands					12 Months Ended
Commitments (Details) ₪ in Thousands, $ in Thousands	Dec. 29, 2025 USD ($)	Dec. 29, 2025 ILS (₪)	Nov. 11, 2025 USD ($)	Dec. 22, 2022 USD ($)	Dec. 31, 2025 USD ($) m²	Dec. 31, 2024 USD ($)	Feb. 27, 2025 USD ($)	Nov. 13, 2022
Commitments [Line Items]
Agreement, term								10 years
Termination, term								180 days
Development milestone payments					$ 6,381	$ 6,324
Cost of revenue					$ 1,987
Ares of land (in Square Meters) \| m²					264
Expenses related to leases			$ 54		$ 238	265
Operating lease					292	$ 264
Agreement and committed	$ 2,185	₪ 7,000			$ 75,000
Minimum [Member]
Commitments [Line Items]
Lease payments					3.00%
Maximum [Member]
Commitments [Line Items]
Lease payments					7.00%
Previously Reported [Member]
Commitments [Line Items]
Cost of revenue					$ 59
Medicox License Agreement [Member]
Commitments [Line Items]
Fixed consideration				$ 2,000
Development milestone payments				$ 15,000
Sales-based royalties, percentage				15.00%
Israel Innovation Authority (“IIA”) [Member]
Commitments [Line Items]
Royalties percentage					3.00%
Interest amount					$ 2,213
Interest received					$ 2,570
Payment obligation							$ 2,046
Israel Innovation Authority (“IIA”) [Member] \| Minimum [Member]
Commitments [Line Items]
Royalties percentage					100.00%
Israel Innovation Authority (“IIA”) [Member] \| Maximum [Member]
Commitments [Line Items]
Royalties percentage					150.00%
Clinical Research Organization (CRO) [Member]
Commitments [Line Items]
Term of the engagement					$ 11,577
Recognized in research and development expenses					$ 1,406

Taxes on Income - Schedule of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Schedule of Unrecognized Tax Benefits [Abstract]
Balance at Beginning of Year		$ 11
Decrease in uncertain tax positions for the current year		(11)
Balance at End of Year

Stock-Based Compensation - Schedule of Concerning the Options Granted to Employees and Directors Outstanding (Details) - Employees and Directors [Member]	12 Months Ended
	Dec. 31, 2025 $ / shares shares
Schedule of Concerning the Options Granted to Employees and Directors Outstanding [Line Items]
Number outstanding \| shares	1,660,383
Weighted Average Remaining Contractual Life Years	4 years 7 days
Weighted average exercise price \| $ / shares	$ 7.21
Exercise prices 1-6 [Member]
Schedule of Concerning the Options Granted to Employees and Directors Outstanding [Line Items]
Number outstanding \| shares	840,500
Weighted Average Remaining Contractual Life Years	3 years 9 months 29 days
Weighted average exercise price \| $ / shares	$ 3.94
Exercise prices 6.23-9.12 [Member]
Schedule of Concerning the Options Granted to Employees and Directors Outstanding [Line Items]
Number outstanding \| shares	283,008
Weighted Average Remaining Contractual Life Years	1 year 9 months 18 days
Weighted average exercise price \| $ / shares	$ 7.96
Exercise prices 10.40-20.19 [Member]
Schedule of Concerning the Options Granted to Employees and Directors Outstanding [Line Items]
Number outstanding \| shares	536,875
Weighted Average Remaining Contractual Life Years	5 years 6 months
Weighted average exercise price \| $ / shares	$ 11.94

Significant Accounting Policies (Details) - USD ($) $ in Thousands			1 Months Ended	12 Months Ended
	Nov. 11, 2025	Jun. 23, 2025	Apr. 30, 2025	Dec. 31, 2025	Dec. 31, 2024	Oct. 30, 2025	Mar. 18, 2021
Significant Accounting Policies [Line Items]
Percentage of issued and outstanding share capital			17.00%				63.00%
Aggregate purchase price	$ 8,501		$ 36,900
Expected liability				12 months
Recognized income				$ 2,000
Purchase warrant (in Shares)				20,000	20,000	100,000
Issuance of fair value		$ 2,727
Aggregate amount				$ 997
Additional period				5 years
Alpha Tau [Member]
Significant Accounting Policies [Line Items]
Recognized income				$ 553
Purchase warrant (in Shares)				3,237,000
Issuance of fair value				$ 2,727
Non cash income				500
Total non cash income				3,000
Deferred income				444
Straight-line income recognition				$ 549
HTIT License Agreement [Member]
Significant Accounting Policies [Line Items]
Aggregate amount received					$ 22,382
Revenue recognized					20,382
Deferred revenues amount					$ 2,000
Minimum [Member]
Significant Accounting Policies [Line Items]
Lease agreements				1 year
Maximum [Member]
Significant Accounting Policies [Line Items]
Lease agreements				5 years
Alpha Tau [Member] \| Minimum [Member]
Significant Accounting Policies [Line Items]
Ownership percentage				20.00%
Alpha Tau [Member] \| Maximum [Member]
Significant Accounting Policies [Line Items]
Ownership percentage				50.00%

Equity Method Investee

12 Months Ended

Dec. 31, 2025

Equity Method Investee [Abstract]

EQUITY METHOD INVESTEE

NOTE 6 – EQUITY METHOD INVESTEE

On October 8, 2024, the Company and certain other investors (“Additional Holders of Note B”) entered into a refinance agreement with Scilex. As part of the refinancing, the Company and the Additional Holders of Note B were granted rights to receive royalties from certain Scilex products. In connection with these rights, on January 2, 2025, the Additional Holders of Note B established RoyaltyVest Ltd. (“RoyaltyVest”), a company incorporated in the British Virgin Islands. On February 12, 2025, the Additional Holders of Note B transferred to the Company 50% of the issued and outstanding capital stock of RoyaltyVest.

As of December 31, 2025, the Company hold a 50% equity interest in RoyaltyVest. The Company accounts for this investment using the equity method.

There are no unrecognized losses, guarantees, or commitments related to RoyaltyVest. In addition, no impairment losses were recorded during the reporting periods.

In addition to its original investment in RoyaltyVest, the Company is using RoyaltyVest as a potential investment vehicle for additional transactions conducted in collaboration with the other shareholders of RoyaltyVest.

As such, On March 4, 2025, the Company entered into a loan agreement with RoyaltyVest pursuant to which the Company made a loan to RoyaltyVest in the amount of $7,000 to purchase shares of BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel”). The loan is non-interest bearing and is non-recourse to the BioXcel shares. Repayment of the outstanding principal and yield shall be made from the proceeds of sales of BioXcel shares and warrants. The Company elected to measure the loan under the fair value option, and as such it is presented at fair value. During the year ended December 31, 2025, the Company received $6,251 of the principal amount from RoyaltyVest from the sales of BioXcel.

The transactions below were carried out by RoyaltyVest:

ZTLido License Agreement

As part of the ROW License Term Sheet signed with Scilex under the Tranche B Note, on February 22, 2025, RoyaltyVest, entered into an additional License Agreement with Scilex (“ZTLido License Agreement”). Under the ZTLido License Agreement, RoyaltyVest acquired exclusive rights to develop, manufacture, and commercialize lidocaine-based products, including ZTLido (lidocaine topical system 1.8%) and SP-103, outside the United States. As part of the arrangement, RoyaltyVest and Scilex will each receive 50% of the net profits from the commercialization of these products.

In consideration for the rights to be provided under the proposed ZTLido License Agreement, as more fully described in the ZTLido License Agreement, (a) RoyaltyVest will invest (whether through cash consideration or in-kind payment through the provision of services) $200 per year toward expanding the Product, (b) Scilex will grant RoyaltyVest a worldwide, exclusive right, license and interest to all products rights for the development, out-licensing, commercialization of any Product outside of the United States and other territories, other than certain excluded designated territories ( “ROW Territory”), and (c) each of RoyaltyVest and Scilex will receive 50% percent of the net revenue (less expenses) generated from any product in the ROW Territory.

Ex-U.S. product rights to Gloperba

On February 28, 2025, RoyaltyVest entered into a worldwide (excluding the U.S.) license agreement for Gloperba products, as defined under the License and Commercialization Agreement between RxOmeg Therapeutics LLC and Scilex, dated June 14, 2022, as amended on January 16, 2025 (the “Gloperba License Agreement”). Under the Gloperba License Agreement, RoyaltyVest was granted an exclusive (including as to Scilex Pharma) license to all product-related rights worldwide to develop, manufacture, obtain regulatory approvals for, commercialize, and otherwise exploit the Gloperba products in the licensed territory. RoyaltyVest and Scilex will each be entitled to receive 50% of the net revenue generated from the commercialization of the Gloperba products.

BioXcel

On March 4, 2025, RoyaltyVest participated in a registered direct offering by BioXcel, acquiring 188,383 shares of BioXcel’s common stock, 3,811,617 pre-funded warrants and accompanying warrants to purchase up to an additional 4,000,000 shares for a total consideration of $14,000. The warrants have an exercise price of $4.20 per share, are immediately exercisable, and will expire five years from the date of issuance. The pre-funded warrants have an exercise price of $0.001 per share, and are immediately exercisable with no expiration date.

As of December 31, 2025, RoyaltyVest sold 4,000,000 shares and 2,600,000 warrants for $12,502. As of December 31, 2025, RoyaltyVest continues to hold 1,400,000 warrants and no longer holds any shares of BioXcel common stock.

Financial Income (Loss), Net

12 Months Ended

Dec. 31, 2025

Financial Income (Loss), Net [Abstract]

FINANCIAL INCOME (LOSS), NET:

NOTE 17 - FINANCIAL INCOME (LOSS), NET:

	Year ended December 31,
	2025			2024
Revaluation of investments, net:
Revaluation of Scilex, net (see note 4)		44,647			(4,359	)
Revaluation of Hapisga, net (see note 7)		1,522			-
Revaluation of Alpha Tau, net (see note 8)		36,997			-
Revaluation of RoyaltyVest loan, net (see note 4)		(447	)		-
Revaluation of Profit Sharing Loan Agreement (see note 4)		372			57
Revaluation of Convertible Note (see note 9)		1,636			-
Revaluation of other marketable securities (see note 4)		3,212			(3,114	)
		87,939			(7,416	)
Interest Income		2,373			4,983
Exchange rate		(252	)		174
Other		(606	)		(27	)
	$	89,454		$	(2,286	)

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Pay vs Performance Disclosure
Net Income (Loss)	$ 64,050	$ (19,060)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2025

Stock-Based Compensation [Abstract]

Schedule of Stock Options Granted to Employees and Directors

A summary of the status of the stock options granted to employees and directors as of December 31, 2025 and 2024 and changes during the years ended on those dates, is presented below:

	Year ended December 31,
	2025					2024
	Number of options			Weighted average exercise price		Number of options			Weighted average exercise price
				$					$
Options outstanding at beginning of year		1,661,008			7.21		1,909,676			8.03
Changes during the year:
Granted		-			-		-			-
Forfeited		(625	)		13.89		(49,125	)		13.92
Expired		-			-		(199,543	)		13.40
Exercised		-			-		-			-
Options outstanding at end of year		1,660,383			7.21		1,661,008			7.21
Options exercisable at end of year		1,501,633			7.18		1,442,258			6.91

Schedule of Concerning the Options Granted to Employees and Directors Outstanding

The following table presents summary information concerning the options granted to employees and directors outstanding as of December 31, 2025:

Exercise prices $	Number outstanding		Weighted Average Remaining Contractual Life Years		Weighted average exercise price $
1-6		840,500		3.83		3.94
6.23-9.12		283,008		1.80		7.96
10.40-20.19		536,875		5.50		11.94
		1,660,383		4.02		7.21

Schedule of Concerning the Options Granted to Non Employees Outstanding

The following table presents summary information concerning the options granted to non-employees outstanding as of December 31, 2025:

Range of exercise prices $		Number outstanding				Weighted Average Remaining Contractual Life Years				Weighted Average Exercise Price $
3.74-5.08			47,000				3.98				4.31

Schedule of Unvested RSUs and PSUs Granted to Employees and Directors

The following table summarizes the activities for unvested RSUs and PSUs granted to employees and directors for the years ended December 31, 2025 and 2024:

	Year ended December 31,
	2025			2024
	Number of RSUs
Outstanding at the beginning of year		2,572,065			1,834,362
Changes during the year:
Granted		3,228,791			1,792,460
Issued		(1,410,437	)		(617,542	)
Forfeited		(6,925	)		(386,445	)
Expired		-			(50,770	)
Outstanding at the end of the year		4,383,494			2,572,065
Vested during the year		1,880,104			925,937
Vested and unissued at year end		952,928			483,261

Short-Term Deposits (Tables)

12 Months Ended

Dec. 31, 2025

Short-Term Deposits [Abstract]

Schedule of Short Term Deposits

Composition:

	December 31,
	2025					2024
	Annual interest rate			Amount		Annual interest rate			Amount
Dollar deposits		4.15-5.10	%		10,979		5.65-5.75	%		55,281

Convertible Secured Promissory Note (Tables)

12 Months Ended

Dec. 31, 2025

Convertible Secured Promissory Note [Abstract]

Schedule of Assumptions and Estimates that Were Used for the Valuation

Presented below is the summary of the assumptions and estimates that were used for the valuation as of December 31, 2025:

Parameters and Assumptions
Share Price	$	0.58
Conversion Rate		0.45
Maturity Date		May 14, 2026
Volatility		113.38	%
Risk Free Rate		3.30	%
Yield		27.76	%

Investments, at Fair Value (Tables)

12 Months Ended

Dec. 31, 2025

Investments, at Fair Value [Abstract]

Schedule of Fair Value Composition

The table below represents the fair value composition of the Tranche A Note:

	December 31, 2025		December 31, 2024
Tranche A Note	$	23,063	$	13,714
Subsequent Penny Warrants	$	-	$	2,772
Total	$	23,063	$	16,486

The table below represents the fair value composition of the Tranche B Note:

	December 31, 2025						December 31, 2024
	Short term		Long term		Total		Short term		Long term		Total
Tranche Note B	$	11,473	$	-	$	11,473	$	11,263	$	4,535	$	15,798
Warrant	$	-	$	850	$	850	$	-	$	548	$	548
Royalty Purchase Agreement	$	1,072	$	1,137	$	2,209	$	1,039	$	937	$	1,976
Total	$	12,545	$	1,987	$	14,532	$	12,302	$	6,020	$	18,322

Schedule of Assumptions and Estimates Valuation

Presented below is the summary of the assumptions and estimates that were used for the valuation as of December 31, 2025:

Parameters and Assumptions
Share Price	$	12.20
Conversion Rate		36.40
Floor Rate		36.40
Expected Term		0.77
Volatility		66.39	%
Risk Free Rate		3.44	%
Yield		75.09	%

Presented below is the summary of the assumptions and estimates that were used for the valuation of the Warrants as of December 31, 2025:

Parameters and Assumptions
Share Price	$	12.20
Exercise Price	$	20 – 36.4
Expected Term		3.77 – 3.95
Volatility		68.63 – 68.27	%
Risk Free Rate		3.57 – 3.58	%
Dividend Rate		0	%

Schedule of Refinancing Transaction

The table below represents the fair value cycle of 2023 Scilex Transaction and 2024 Refinancing Transaction throughout December 31, 2024 and December 31, 2025:

	Tranche A			Tranche B			Total
Balance as of December 31, 2023	$	110,188			-		$	110,188
2024 Refinancing		(21,575	)		25,000			3,425
Proceeds from the sale of Transferred Warrants		(300	)		-			(300	)
Cash received from Tranche A Note repayment		(64,200	)		-			(64,200	)
Exercised warrants (*)		(6,123	)		-			(6,123	)
Amounts receivable from the royalty agreement		-			(398	)		(398	)
Change in fair value		(1,504	)		(6,280	)		(7,784	)
Balance as of December 31, 2024		16,486			18,322			34,808
Amounts receivable from the royalty agreement (**)		-			(1,640	)		(1,640	)
Principal payments					(9,875	)		(9,875	)
Proceeds from the sale of Subsequent Penny Warrants		(28,500	)		-			(28,500	)
Interest payments					(1,845	)		(1,845	)
Change in fair value		35,077			9,570			44,647
Balance as of December 31, 2025	$	23,063		$	14,532		$	37,595

(*)

On October 30, 2024 the Company exercised 128,572 Closing Penny Warrants, and 57,143 Subsequent Penny Warrants into 185,715 shares of common stock of Scilex and as a result, these shares are not part of the Tranche A Note. As of December 31, 2025, the Company no longer holds any shares of Scilex common stock.

(**)	As of December 31, 2025, out of this amount $449 is included under prepaid expenses and other current assets.

Schedule of Fair Value Breakdown

The table below represents the fair value breakdown as of December 31, 2025:

	Tranche A Note						Tranche B Note						Total
	Amount		Accrued Interest		Fair Value		Amount		Accrued Interest		Fair Value		Fair Value
Notes	$	7,675	$	17,153	$	23,063	$	15,125	$	341	$	11,473	$	34,536
Warrants		-		-		-		207,143		-	$	850	$	850
Royalty Purchase Agreement payment		-		-		-		-		-	$	2,209	$	2,209
December 31, 2025					$	23,063				-	$	14,532	$	37,595

Marketable Securities (Tables)

12 Months Ended

Dec. 31, 2025

Marketable Securities [Abstract]

Schedule of Marketable Securities Include Investments in Equity Securities

The Company’s marketable securities include investments in equity securities of DNA, Entera, Scilex, Nano and Pelthos.

	December 31,
	2025		2024
Short-term:
DNA (see b below)	$	540	$	424
Entera (see c below)		227		248
Scilex (see d below)		-		2,769
Pelthos (see f below)		4,650		-
	$	5,417		3,441

	December 31,
	2025		2024
Long-term:
Nano (see e below)		8,371		-
	$	8,371		-

Stock-Based Compensation - Schedule of Unvested RSUs and PSUs Granted to Employees and Directors (Details) - Restricted Stock Units (RSUs) [Member] - shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Number of RSUs
Number of RSUs, Outstanding at the beginning of year	2,572,065	1,834,362
Number of RSUs, Granted	3,228,791	1,792,460
Number of RSUs, Issued	(1,410,437)	(617,542)
Number of RSUs, Forfeited	(6,925)	(386,445)
Number of RSUs, Expired		(50,770)
Number of RSUs, Outstanding at the end of the year	4,383,494	2,572,065
Number of RSUs, Vested during the year	1,880,104	925,937
Number of RSUs, Vested and unissued at year end	952,928	483,261

Short-Term Deposits

12 Months Ended

Dec. 31, 2025

Short-Term Deposits [Abstract]

SHORT-TERM DEPOSITS

NOTE 2 - SHORT-TERM DEPOSITS:

Composition:

	December 31,
	2025					2024
	Annual interest rate			Amount		Annual interest rate			Amount
Dollar deposits		4.15-5.10	%		10,979		5.65-5.75	%		55,281

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
Cybersecurity Risk Management and Strategy Disclosure	Dec. 31, 2025
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	The Board recognizes the critical importance of maintaining the trust and confidence of our business partners, employees and clinical trial participants. The Audit Committee is responsible for reviewing our policies with respect to cybersecurity risks and relevant contingent liabilities and risks that may be material to the Company, including risks from third parties and business partners. We generally seek to address cybersecurity risks by implementing security measures on our internal computer systems and ensuring that third parties and business partners implement similar measures. These security measures include firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated by our external IT consultant and improved through vulnerability assessments and cybersecurity threat intelligence. Our Chief Operating and Business Officer is responsible for implementing protection measures for our information systems from cybersecurity threats and promptly responding to any cybersecurity incidents. To date, risks from cybersecurity threats have not materially affected us and we do not currently believe any risks from cybersecurity threats are reasonably likely to affect the Company, including our business strategy, results of operations or financial condition. For further information, see “Item 1A. Risk Factors,” under “Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.”
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	We generally seek to address cybersecurity risks by implementing security measures on our internal computer systems and ensuring that third parties and business partners implement similar measures. These security measures include firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated by our external IT consultant and improved through vulnerability assessments and cybersecurity threat intelligence.
Cybersecurity Risk Role of Management [Text Block]	Our Chief Operating and Business Officer is responsible for implementing protection measures for our information systems from cybersecurity threats and promptly responding to any cybersecurity incidents.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	Chief Operating and Business Officer
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]	To date, risks from cybersecurity threats have not materially affected us and we do not currently believe any risks from cybersecurity threats are reasonably likely to affect the Company
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false

Accounts Payable and Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2025

Accounts Payable and Accrued Expenses [Abstract]

Schedule of Accounts Payable and Accrued Expenses

Composition:

	December 31,
	2025		2024
Accounts payable	$	443	$	789
Payroll and related accruals		755		407
Income tax		3,286		3,204
Accrued liabilities – Legal Fee		1,084		402
Accrued liabilities – Other		633		338
	$	6,201	$	5,140

Taxes on Income (Tables)

12 Months Ended

Dec. 31, 2025

Taxes on Income [Abstract]

Schedule of Deferred Income Taxes

Deferred income taxes

	December 31,
	2025			2024
In respect of:
Net operating loss carryforward	$	27,306		$	26,797
Research and development expenses		1,005			1,220
Revaluation of investments		(7,973	)		5,608
Other temporary differences		134			2,495
Less - valuation allowance		(28,383	)		(36,120	)
Net deferred tax liability	$	(7,911	)	$	-

Schedule of Income (Loss) Before Taxes on Income

Income (Loss) before taxes on income and income taxes included in the consolidated statements of comprehensive income (loss)

	Year ended December 31,
	2025			2024
Income (loss) before taxes on income:
U.S.	$	46,424		$	(8,853	)
Outside U.S.		28,900			(7,067	)
	$	75,324		$	(15,920	)
Taxes on income (tax benefit):
Current:
U.S.		3,573			3,183
Outside U.S.		-			-
	$	3,573		$	3,183

Deferred Taxes:
U.S.	$	(184	)	$	-
Outside U.S.		8,095			-
	$	7,911		$	-
Prior Year Taxes:
U.S.		(176	)		-
Outside U.S.		-			-
	$	(176	)	$	-

Total Taxes:
U.S.	$	3,213		$	3,183
Outside U.S.		8,095			-
	$	11,308		$	3,183

Schedule of Assuming all Income is Taxed at Regular Tax Rates Applicable to Companies in United States, and Actual Tax Expense

The amounts for 2024 are presented prior to the adoption of ASU 2023-09, while the amounts for 2025 are presented after its adoption.

	2024
Income (loss) before taxes expenses	$	(15,920	)

Statutory tax (benefit) expense – 21%		(3,343	)
Increase (decrease) in income taxes resulting from:
Change in valuation allowance		7,647
Disallowable deductions		(878	)
Influence of different tax rate applicable to the Subsidiary and Oravax Medical Ltd.		(219	)
Prior year adjustments		(13	)
Uncertain tax position		(11	)
Taxes on income for the reported year	$	3,183

Year ended December 31, 2025

	Amount			Percent
U.S. federal statutory tax rate	$	15,818			21
Foreign tax effects
Israel
Share-based payment awards		2,573			3.4
Changes In Valuation allowance		(1,137	)		(1.5	)
Statutory tax rate difference between Israel and United States		579			0.8
Other		13			0.0
Effect of cross-border tax laws		114			0.2
Change in the valuation allowance		(6,600	)		(8.8	)
Nontaxable or nondeductible items		122			0.2
Other		(174	)		(0.2	)
Effective Tax Rate	$	11,308			15.0

Schedule of Unrecognized Tax Benefits

The following table summarizes the activity of the Company unrecognized tax benefits:

	Year ended December 31,
	2025		2024
Balance at Beginning of Year	$	-	$	11
Decrease in uncertain tax positions for the current year		-		(11	)
Balance at End of Year	$	-	$	-

Schedule of Valuation Allowance Rollforward

Valuation Allowance Rollforward

	Year ended
	Balance at beginning of year		Additions (deductions)			Balance at end of year
Allowance in respect of carryforward tax losses:
Year ended December 31, 2025	$	36,120	$	(7,737	)	$	28,383
Year ended December 31, 2024	$	28,473	$	7,647		$	36,120

Subsequent Events

12 Months Ended

Dec. 31, 2025

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 21 - SUBSEQUENT EVENTS:

2023 Scilex Transaction and 2024 Refinancing

In connection with Note 4, regarding the Tranche B Note, on January 7, 2026, the Company received a repayment from Scilex of $3,396 ($3,125 of the principal amount and $271 interest). On February 27, 2026, the Company received a payment of $395 from Scilex representing royalties owed for the three months ended December 31, 2025.

Dividend

In connection with Note 14, on January 22, 2026, the Company distributed a dividend in the amount of $10,061 to its shareholders.

PSUs vested

In connection with Note 15, during January 2026, the applicable market condition related to 166,000 PSUs previously granted to the Company’s executive officers was satisfied. As a result, such PSUs vested in full.

Nano

Subsequent to December 31, 2025 and through March 26, 2026, the Company purchased an additional 6,401,939 ordinary shares of Nano for an aggregate purchase price of $12,308 and the Company sold 1,269,987 ordinary shares of Nano for aggregate proceeds of $2,606. Following these transactions, the Company holds an aggregate of 10,568,743 ordinary shares of Nano, representing approximately 5.02% of its outstanding share capital as of March 26, 2026.

Pelthos

Subsequent to December 31, 2025 and through March 26, 2026, the Company sold 6,577 shares of Pelthos common stock for aggregate proceeds of $173. Following these sales, the Company hold 143,423 shares of Pelthos common stock.

Lifeward

In connection with note 9, on February 12, 2026, we agreed to provide Lifeward with an additional secured promissory note with an initial principal amount of $525, which may be increased by up to an additional $975, bearing interest at 24% per annum and secured by a lien on Lifeward’s cash. As of March 26, 2026, we had funded $1,025 under this additional note.

The outstanding principal and accrued interest under the secured promissory notes are expected to be rolled into the Initial Notes issued under the Lifeward Notes Purchase Agreement described below.

Lifeward Share Purchase Agreement

On January 12, 2026, the Company entered into a Share Purchase Agreement (“Lifeward Share Purchase Agreement”) with Lifeward and OraTech pursuant to which Lifeward agreed to acquire all of the outstanding equity interests of OraTech from the Company (“Share Purchase Transaction”). Prior to the closing, the Company transferred to OraTech all intellectual property and related assets relating to our POD™ (Protein Oral Delivery) technology platform, together with cash to fund the next planned clinical trial and related development activities. As a result, commencing on the closing date of March 25, 2026, research and development expenses will be borne by OraTech.

In consideration for the acquisition of Oratech, Lifeward issued to us: (i) Lifeward Ordinary Shares and pre-funded warrants to purchase Lifeward Ordinary Shares representing up to 49.99% of Lifeward’s fully diluted equity capitalization at closing, subject to adjustments, representing less than 45.0% of the outstanding Lifeward Ordinary Shares at closing; (ii) warrants to purchase Lifeward Ordinary Shares equal to the quotient of Lifeward’s net cash at closing divided by an exercise price of $5.40 per share, reflecting Lifeward’s 12-for-1 reverse share split effected on February 24, 2026 (which adjusted the original exercise price of $0.45 per share), subject to adjustments (“Share Purchase Warrants”), and (iii) revenue-sharing payments equal to 4% of the net revenue from Lifeward’s ReWalk Personal Exoskeleton products and related extended warranties for up to 10 years following closing, subject to certain caps and early termination upon the occurrence of specified events.

The closing of the Initial Notes was subject to customary closing conditions, including the approval of Lifeward’s shareholders for the issuance of more than 19.99% of Lifeward Ordinary Shares in accordance with Nasdaq listing standards. Such shareholder approval was obtained on March 12, 2026.

In connection with the transaction, Lifeward agreed to file a resale registration statement with the SEC covering the Lifeward Ordinary Shares issued in the transaction and those issuable upon exercise of the pre-funded warrants and warrants described above as soon as practicable following closing, but no later than 75 days after closing, and to use commercially reasonable efforts to have such registration statement declared effective within 75 days after closing (or 105 days in the event of a full SEC review).

Pre-Funded Warrants and Share Purchase Warrants

The Share Purchase Warrants will be immediately exercisable upon issuance at an initial exercise price of $5.40 per share, reflecting Lifeward’s 12-for-1 reverse share split effected on February 24, 2026 (which adjusted the original exercise price of $0.45 per share), and will expire five years from the date of issuance. The exercise price is subject to customary anti-dilution adjustments.

The Pre-Funded Warrants will have an exercise price of $0.0012 per share (reflecting the reverse-split adjusted price of the original $0.0001 per share), subject to customary adjustments, and will remain exercisable until exercised in full.

The Company may not exercise any portion of the Pre-Funded Warrants or Share Purchase Warrants to the extent that, after giving effect to such exercise, the Company and our affiliates would beneficially own more than 45.0% of the outstanding Lifeward Ordinary Shares. This limitation will automatically increase to 49.99% once (i) the Investors no longer hold any Notes and (ii) the Investors have sold all Note Shares issued or issuable upon conversion of the Notes and related warrants. The Company may increase the beneficial ownership limitation upon at least 61 days’ prior notice to Lifeward; provided that, for so long as certain Lifeward warrants outstanding as of the issuance date remain outstanding, any such increase will require Lifeward’s consent, which may not be unreasonably withheld, conditioned or delayed.

In connection with the execution of the Lifeward Share Purchase Agreement, the Company entered into a lock-up agreement for a period of 120 days after the Closing, without the prior written consent of Lifeward.

Clinical Trial Management Agreement

In connection with the Lifeward Share Purchase Agreement, the Company agreed to entered into a clinical trial management (the “Clinical Trial Management Agreement”) with Oratech, pursuant to which the Company agreed to manage the clinical study of Oratech’s investigational oral insulin capsule product (the “Study”), including providing clinical trial management and administrative services through study completion (the “Services”). In consideration for the Services, OraTech will reimburse to the Company for all reasonable out-of-pocket expenses actually incurred by the Company in providing the Services and payments made on behalf of OraTech to third parties and vendors, such as clinical sites, if applicable, subject to certain limitations and maximum payments as set forth in the Clinical Trial Management Agreement. The Clinical Trial Management Agreement will terminate upon completion of the Study unless earlier terminated in accordance with the terms set forth therein.

Notes Securities Purchase Agreement

On January 12, 2026, the Company entered into a Securities Purchase Agreement (the “Lifeward Notes Purchase Agreement”) with Lifeward and other investors pursuant to which the Company agreed to purchase, in a private placement, up to $18,000 of senior secured convertible notes issued by Lifeward, together with accompanying warrants to purchase Lifeward Ordinary Shares.

At the initial closing, which occurred on March 25, 2026, the Company agreed to purchase $9,000 aggregate principal amount of such notes (the “Initial Notes”). The Notes bear interest at 8% per annum, payable semi-annually, and mature three years from the date of issuance. The Notes are convertible into Lifeward Ordinary Shares at an initial conversion price of $5.40 per share, reflecting Lifeward’s 12-for-1 reverse share split effected on February 24, 2026 (which adjusted the original conversion price of $0.45 per share), subject to customary anti-dilution adjustments.

The Company also agreed to purchase an additional $9,000 aggregate principal amount of notes (the “Additional Notes”) and together with the Initial Notes (the “Notes”) together with accompanying warrants, on substantially the same terms as the Initial Notes.

The closing of the Additional Notes is subject to customary closing conditions and either:

(i) Lifeward achieving at least a 150% increase in ReWalk unit sales compared to the trailing twelve-month period immediately preceding the Additional Closing; or

(ii) the closing price of Lifeward Ordinary Shares equaling or exceeding $13.80 per share, reflecting Lifeward’s 12-for-1 reverse share split (which adjusted the original $1.15 threshold), for 10 consecutive trading days immediately prior to the Additional Closing.

The closing of the Notes was subject to customary closing conditions, including the approval of Lifeward’s shareholders for the issuance of more than 19.99% of Lifeward Ordinary Shares in accordance with Nasdaq listing standards. Such shareholder approval was obtained on March 12, 2026.

In connection with the transaction, Lifeward agreed to file a resale registration statement with the SEC covering the Lifeward Ordinary Shares issuable upon conversion of the Notes and exercise of the related warrants within 30 days after the Initial Closing, and to use commercially reasonable efforts to have the registration statement declared effective within 45 days thereafter (or 75 days in the event of a full SEC review).

Company is currently evaluating the accounting treatment of these transactions and the impact on its consolidated financial statements.

Ruby Sapphire II Investment

In connection with Note 13, on February 5, 2026, the Company had funded NIS 1,556 ($499) under this commitment. The Company is currently evaluating the accounting treatment of these transactions and the impact on its consolidated financial statements.

Corner Ally Ventures

On March 1, 2026, the Company’s board approved the formation of Corner Ally Ventures (the “Fund”), a venture capital fund focused on investments in Israeli technology companies. The Company co-founded the Fund together with Corner Capital Management, LLC and, together with Ben Shapiro, is expected to serve as a general partner of the Fund and participate in its management and investment decision-making and may be entitled to a share of the Fund’s carried interest. The Company also expects to serve as an anchor limited partner and has committed to invest up to $40,000 in the Fund, which is expected to be funded over an anticipated four-year capital call period. The Fund’s initial closing, subject to a minimum capital commitment of $75,000, is expected to occur in the third quarter of 2026. The Company is currently evaluating the accounting treatment of this arrangement and the impact, if any, on its consolidated financial statements.

RSU Grant

On March 17, 2026, the Company granted an aggregate of 478,341 RSUs representing a right to receive shares of the Company’s common stock to executive officers of the Company. The RSUs will vest in eight equal quarterly installments starting April 1, 2026.

Taxes on Income - Schedule of Valuation Allowance Rollforward (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Allowance in respect of carryforward tax losses:
Balance at beginning of year	$ 36,120	$ 28,473
Additions (deductions)	(7,737)	7,647
Balance at end of year	$ 28,383	$ 36,120

Investment in Associate at Fair Value - Schedule of Financial Information (Details) - Alpha Tau [Member] $ in Thousands	8 Months Ended
	Dec. 31, 2025 USD ($)
Condensed Financial Statements, Captions [Line Items]
Cash	$ 12,202
Short-term deposits	60,924
Other current assets	5,172
Non-current assets	27,354
Total assets	105,652
Current liabilities	10,507
Non-current liabilities	18,046
Shareholders’ equity	77,099
Total liabilities and stockholders’ deficit	105,652
Net loss	$ 29,313

Other Non-Marketable Equity Securities (Details) - USD ($) $ in Thousands		12 Months Ended
	Aug. 26, 2022	Dec. 31, 2025	Dec. 31, 2024
Other Non-Marketable Equity Securities [Abstract]
Aggregate purchase amount	$ 2,700
Percentage of shares hold of issued and outstanding	5.00%
Change in the value of investment

Income (Loss) Per Share of Common Stock

12 Months Ended

Dec. 31, 2025

Income (Loss) Per Share of Common Stock [Abstract]

INCOME (LOSS) PER SHARE OF COMMON STOCK

NOTE 16 – INCOME (LOSS) PER SHARE OF COMMON STOCK:

The following table summarizes the calculation of basic and diluted income per common stock (in thousands, except for share and per share amounts):

	Year ended December 31,
	2025			2024
Basic income (loss) per common stock (numerator):
Net income (loss) applicable to common stock		64,050			(19,060	)
Adjustment for dividends attributable to unvested RSUs		(808	)		-
Net income (loss) applicable to common stock – basic		63,242			(19,060	)
common stock (denominator):
Weighted average number of common stock – basic		41,402,997			40,850,446
Basic income (loss) per common stock		1.53			(0.48	)

Diluted income (loss) per common stock (numerator):
Net income (loss) applicable to common stock – basic		63,242			(19,060	)
Adjustment for dividends attributable to unvested RSUs		359			-
Net income (loss) applicable to common stock – diluted		63,601			(19,060	)
common stock (denominator):
Weighted average number of common stock – basic		41,402,997			40,850,446
Diluted effect of RSUs		1,015,647			-
Weighted average number of common stock – diluted		42,418,644			40,850,446
Diluted income (loss) per common stock		1.50			(0.48	)

For the year ended December 31, 2025, options to purchase common stock, RSUs and warrants totaling 1,847,946 were excluded from the calculation of diluted income per common stock, as their effect was antidilutive. As the Company had a net loss for the year ended December 31, 2024, all potentially dilutive common stock, including options, warrants and RSUs totaling 3,549,490, were considered antidilutive and therefore excluded from the calculation of diluted income per common stock for the period.

Subsequent Events (Details) $ / shares in Units, ₪ in Thousands														1 Months Ended	12 Months Ended
	Mar. 17, 2026 shares	Feb. 27, 2026 USD ($)	Feb. 24, 2026 $ / shares	Feb. 12, 2026 USD ($) $ / shares	Feb. 05, 2026 USD ($)	Feb. 05, 2026 ILS (₪)	Jan. 22, 2026 USD ($) shares	Jan. 12, 2026 USD ($)	Jan. 07, 2026 USD ($)	Dec. 29, 2025 USD ($)	Dec. 29, 2025 ILS (₪)	Nov. 11, 2025 USD ($) shares	Apr. 14, 2025	Apr. 30, 2025 USD ($)	Dec. 31, 2025 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares
Subsequent Events [Line Items]
Repaid amount																$ 49,550,000
Aggregate purchase price												$ 8,501,000		$ 36,900,000
Company sold ordinary shares (in Shares) \| shares															350,000
Aggregate proceeds															$ 997,000
Promissory note				$ 525,000
Additional principal amount				975,000
Additional funded				$ 1,025,000
Equity capitalized adjusted percentage				49.99%
Ordinary shares closing percentage				45.00%
Exercise price per share (in Dollars per share) \| $ / shares				$ 5.4
Revenue sharing payment percentage															4.00%
Stock issued percentage															19.99%
Purchase price per share (in Dollars per share) \| $ / shares															$ 4.13	$ 4.13
Pre-Funded Warrants exercise price (in Dollars per share) \| $ / shares															0.0012
Reverse-split adjusted price (in Dollars per share) \| $ / shares															0.0001
Reverse-split adjusted price (in Dollars per share) \| $ / shares															$ 45
Automatically increase percentage															49.99%
Private placement								$ 18,000,000
Annual interest percentage															8.00%
Conversion price (in Dollars per share) \| $ / shares			$ 0.45
Percentage of ReWalk sales															150.00%
Reverse share split													1-for-35		12-for-1
Consecutive trading days															10 days
Percentage of lifeward ordinary shares															19.99%
Warrants terms															30 days
Limited parrtners committed investment															$ 40,000,000
Committed invest fund										$ 2,185,000	₪ 7,000				$ 75,000,000
Pre-Funded Warrants and Share Purchase Warrants [Member]
Subsequent Events [Line Items]
Purchase price per share (in Dollars per share) \| $ / shares															$ 5.4
Adjusted exercise price															0.45%
Initial Notes [Member]
Subsequent Events [Line Items]
Initial conversion price per share (in Dollars per share) \| $ / shares			5.4
Ordinary Shares [Member]
Subsequent Events [Line Items]
Company sold ordinary shares (in Shares) \| shares												5,436,791
Price per share (in Dollars per share) \| $ / shares															$ 13.8
Reverse stock split per share (in Dollars per share) \| $ / shares															$ 1.15
Nano [Member]
Subsequent Events [Line Items]
Purchased an additional shares (in Shares) \| shares															6,401,939
Aggregate proceeds															$ 2,606
Aggregate shares (in Shares) \| shares												10,568,743
Percentage of outstanding share capital															5.02%
Nano [Member] \| Ordinary Shares [Member]
Subsequent Events [Line Items]
Aggregate purchase price															$ 12,308,000
Company sold ordinary shares (in Shares) \| shares															1,269,987
Pelthos [Member]
Subsequent Events [Line Items]
Company sold ordinary shares (in Shares) \| shares															6,577
Aggregate proceeds															$ 173
Shares hold (in Shares) \| shares															143,423
Notes Securities Purchase Agreement [Member]
Subsequent Events [Line Items]
Private placement															$ 9,000,000
Aggregate principal amount															9,000,000
Scilex [Member]
Subsequent Events [Line Items]
Repaid amount															$ 9,875,000
Subsequent Event [Member]
Subsequent Events [Line Items]
Repaid amount									$ 3,396,000
Cash payments received		$ 395
Company distributed a dividend							$ 10,061
Previously granted executive officers (in Shares) \| shares							166,000
Annum and secured interest percentage				24.00%
Exercise price per share (in Dollars per share) \| $ / shares			$ 0.45
Reverse share split			12-for-1
Funded amount					$ (499,000)	₪ 1,556
Restricted shares (in Shares) \| shares	478,341
Subsequent Event [Member] \| Tranche B Note [Member]
Subsequent Events [Line Items]
Accrued interest									271,000
Subsequent Event [Member] \| Scilex [Member] \| Tranche B Note [Member]
Subsequent Events [Line Items]
Principal amount									$ 3,125,000

Investment in Associate at Fair Value (Tables)

12 Months Ended

Dec. 31, 2025

Investment In Associate At Fair Value [Abstract]

Schedule of Financial Information

The following presents summarized financial information related to Alpha Tau as of December 31, 2025. Alpha Tau is a publicly traded company listed on the Nasdaq Capital Market, and its financial information is based on publicly available filings.

	December 31, 2025
Cash	$	12,202
Short-term deposits		60,924
Other current assets		5,172
Non-current assets		27,354
Total assets		105,652
Current liabilities		10,507
Non-current liabilities		18,046
Shareholders’ equity		77,099
Total liabilities and stockholders’ deficit		105,652

		April 24, 2025 - December 31, 2025
Net loss		$	29,313

Schedule of Valuation of the Warrants

Presented below is the summary of the assumptions and estimates that were used for the valuation of the Alpha Tau warrants as of June 23, 2025, the issuance date, and December 31, 2025:

	As of
Parameters and Assumptions	June 23, 2025			December 31, 2025
Share Price	$	2.985		$	4.95
Exercise Price		$ 3.47-3.9			$ 3.47-3.9
Expected Term		2.35			1.81
Volatility		55.61	%		49.04	%
Risk Free Rate		3.89	%		3.47	%
Dividend Rate		0	%		0	%

Convertible Secured Promissory Note (Details) - USD ($) $ / shares in Units, $ in Thousands				12 Months Ended
	Feb. 24, 2026	Nov. 14, 2025	Apr. 14, 2025	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Convertible Secured Promissory Note [Line Items]
Secured promissory note amount		$ 3,000		$ 3,000
Bearing interest rate		15.00%
Secured promissory note maturity date		May 14, 2026
Reverse share split			1-for-35	12-for-1
Discount rate				32.00%
Fair value of secured promissory amount				$ 4,637
Changes in the fair value of the secured promissory				$ 1,637	$ (7,784)	$ 44,647
Subsequent Event [Member]
Convertible Secured Promissory Note [Line Items]
Conversion price per share (in Dollars per share)	$ 5.4
Reverse share split	12-for-1
Adjusted conversion price (in Dollars per share)	$ 0.45

Short-Term Deposits - Schedule of Short Term Deposits (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Schedule of Short Term Deposits [Line Items]
Deposits amount (in Dollars)	$ 10,979	$ 55,281
Minimum [Member]
Schedule of Short Term Deposits [Line Items]
Annual interest rate	4.15%	5.65%
Maximum [Member]
Schedule of Short Term Deposits [Line Items]
Annual interest rate	5.10%	5.75%

- Definition

Rate of interest on investment.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477439/946-210-55-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.12-12A(Column A)(Footnote 2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.12-12A(Column A)(Footnote 3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

+ Details

Convertible Secured Promissory Note

12 Months Ended

Dec. 31, 2025

Convertible Secured Promissory Note [Abstract]

CONVERTIBLE SECURED PROMISSORY NOTE

NOTE 9 – CONVERTIBLE SECURED PROMISSORY NOTE

On November 14, 2025, in anticipation of the transactions contemplated by the Lifeward Share Purchase Agreement and the Lifeward Notes Purchase Agreement described below, the Company entered into a loan agreement with Lifeward Ltd.(“Lifeward”) pursuant to which the Company provided Lifeward with a $3,000 secured promissory note bearing interest at 15% per annum and maturing on May 14, 2026, unless earlier repaid or converted in accordance with its terms. The note is secured by a lien on Lifeward’s cash and accounts receivable.

The principal and accrued interest under the note are convertible into Lifeward ordinary shares at a conversion price of $5.40 per share, reflecting Lifeward’s 12-for-1 reverse share split effected on February 24, 2026, which adjusted the original conversion price of $0.45 per share.

The Company elected the fair value option in accordance with ASC 825-10, Financial Instruments, for the Secured Promissory Note. As a result, the Secured Promissory Note is measured at fair value, with changes in fair value recognized in the comprehensive income statement.

The valuation of the Secured Promissory Note was performed based on the binomial model, using a discount rate of 32%. Presented below is the summary of the assumptions and estimates that were used for the valuation as of December 31, 2025:

Parameters and Assumptions
Share Price	$	0.58
Conversion Rate		0.45
Maturity Date		May 14, 2026
Volatility		113.38	%
Risk Free Rate		3.30	%
Yield		27.76	%

As of December 31, 2025, the fair value of the Secured Promissory Note was $4,637. For the year ended December 31, 2025, the Company recognized a gain of $1,637 related to changes in the fair value of the Secured Promissory Note, which is included in financial income (expense), net in the consolidated statements of comprehensive income (loss). For further details, see note 21.

Income (Loss) Per Share of Common Stock (Tables)

12 Months Ended

Dec. 31, 2025

Income (Loss) Per Share of Common Stock [Abstract]

Schedule of Earnings Per Share

The following table summarizes the calculation of basic and diluted income per common stock (in thousands, except for share and per share amounts):

	Year ended December 31,
	2025			2024
Basic income (loss) per common stock (numerator):
Net income (loss) applicable to common stock		64,050			(19,060	)
Adjustment for dividends attributable to unvested RSUs		(808	)		-
Net income (loss) applicable to common stock – basic		63,242			(19,060	)
common stock (denominator):
Weighted average number of common stock – basic		41,402,997			40,850,446
Basic income (loss) per common stock		1.53			(0.48	)

Diluted income (loss) per common stock (numerator):
Net income (loss) applicable to common stock – basic		63,242			(19,060	)
Adjustment for dividends attributable to unvested RSUs		359			-
Net income (loss) applicable to common stock – diluted		63,601			(19,060	)
common stock (denominator):
Weighted average number of common stock – basic		41,402,997			40,850,446
Diluted effect of RSUs		1,015,647			-
Weighted average number of common stock – diluted		42,418,644			40,850,446
Diluted income (loss) per common stock		1.50			(0.48	)

Loan Agreement Measured in Fair Value (Details) - USD ($) $ in Thousands		1 Months Ended		12 Months Ended
	Mar. 24, 2025	May 31, 2025	Apr. 30, 2025	Dec. 31, 2025	Dec. 31, 2024	Mar. 31, 2025
Loan Agreement Measured in Fair Value [Line Items]
Real estate	$ 22,650
Mortgage amount	$ 890,000
Repaid amount					$ 49,550
Value of loan				1,890
Loan Agreement [Member]
Loan Agreement Measured in Fair Value [Line Items]
Percentage of annual interest rate	12.00%
Tova Chochma Im Nachala Ltd. [Member]
Loan Agreement Measured in Fair Value [Line Items]
Loaned amount			$ 26,921
Repaid amount		$ 500
Value of loan				$ 27,943
Tova Chochma Im Nachala Ltd. [Member] \| Loan Agreement [Member]
Loan Agreement Measured in Fair Value [Line Items]
Loan amount						$ 5,000
Annual interest rate						12.00%
Minimum [Member]
Loan Agreement Measured in Fair Value [Line Items]
Percentage of weighted average cashflows of loan discounted				9.31%
Maximum [Member]
Loan Agreement Measured in Fair Value [Line Items]
Percentage of weighted average cashflows of loan discounted				24.43%

Investments, at Fair Value - Schedule of Fair Value Composition (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Tranche Note A [Member] \| Tranche Note A [Member]
Schedule of Fair Value Composition [Line Items]
Total	$ 23,063	$ 13,714
Tranche Note A [Member] \| Subsequent Penny Warrants [Member]
Schedule of Fair Value Composition [Line Items]
Total		2,772
Tranche Note A [Member] \| Total [Member]
Schedule of Fair Value Composition [Line Items]
Total	23,063	16,486
Tranche Note B [Member]
Schedule of Fair Value Composition [Line Items]
Total	14,532	18,322
Short term	12,545	12,302
Long term	1,987	6,020
Tranche Note B [Member] \| Tranche B Note [Member]
Schedule of Fair Value Composition [Line Items]
Total	11,473	15,798
Short term	11,473	11,263
Long term		4,535
Tranche Note B [Member] \| Warrant [Member]
Schedule of Fair Value Composition [Line Items]
Total	850	548
Short term
Long term	850	548
Tranche Note B [Member] \| Royalty Purchase Agreement [Member]
Schedule of Fair Value Composition [Line Items]
Total	2,209	1,976
Short term	1,072	1,039
Long term	$ 1,137	$ 937

Investment In Real Estate (Details) - 1 months ended Jan. 31, 2025 ₪ in Thousands, $ in Thousands	USD ($)	ILS (₪)
Investment In Real Estate [Abstract]
Total purchase price	$ 1,586	₪ 5,800

Marketable Securities - Schedule of Marketable Securities Include Investments in Equity Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Short-term:
Short-term marketable securities	$ 5,417	$ 3,441
Long-term:
Long-term marketable securities	8,371
DNA [Member]
Short-term:
Short-term marketable securities	540	424
Entera [Member]
Short-term:
Short-term marketable securities	227	248
Scilex [Member]
Short-term:
Short-term marketable securities		2,769
Pelthos [Member]
Short-term:
Short-term marketable securities	4,650
Nano [Member]
Long-term:
Long-term marketable securities	$ 8,371

Investment in Associate at Fair Value

12 Months Ended

Dec. 31, 2025

Investment In Associate At Fair Value [Abstract]

INVESTMENT IN ASSOCIATE AT FAIR VALUE

NOTE 8 - INVESTMENT IN ASSOCIATE AT FAIR VALUE:

On April 24, 2025, the Subsidiary entered into a share purchase agreement with Alpha Tau (“Alpha Tau SPA”), pursuant to which the Subsidiary purchased 14,110,121 (16.65%) ordinary shares, no par value per share, of Alpha Tau in a registered direct offering at a price of $2.612 per share, for an aggregate purchase price of $36,900. The closing of the transaction occurred on April 28, 2025. In connection with the investment, the Subsidiary has the right to nominate two out of eight directors to Alpha Tau’s board of directors, subject to certain conditions. In addition, since the Alpha Tau SPA date and until December 31, 2025, the Company purchased an additional 359,214 shares of Alpha Tau for an aggregate amount of $1,256.

Concurrently, the Subsidiary and Alpha Tau entered into the Services Agreement, pursuant to which the Subsidiary will provide Alpha Tau with investor relations and public relations services. As consideration, Alpha Tau agreed to pay the Subsidiary a fee of $3,000 over three years and to issue to the Subsidiary fully vested warrants to purchase up to 3,237,000 ordinary shares of Alpha Tau, at exercise prices ranging from $3.474 to $3.90 per share (“Alpha Tau Warrants”), which are immediately exercisable. The term of the Service Agreement is three years, with limited termination rights. Amounts recognized under this arrangement are presented under “other income, net” in the consolidated statement of comprehensive income.

Due to the Company’s significant influence over operating and financial policies, Alpha Tau is considered a related party of the Company.

	December 31, 2025
Cash	$	12,202
Short-term deposits		60,924
Other current assets		5,172
Non-current assets		27,354
Total assets		105,652
Current liabilities		10,507
Non-current liabilities		18,046
Shareholders’ equity		77,099
Total liabilities and stockholders’ deficit		105,652

		April 24, 2025 - December 31, 2025
Net loss		$	29,313

The amount presented above reflects Alpha Tau’s total net loss for the period and is calculated on a straight-line basis, as there were no significant transactions during the period.

On April 24, 2025 and December 31, 2025, the fair value of the Company’s investment in Alpha Tau was $36,885 and $71,623, respectively. The Company recognized an unrealized gain on its investment in Alpha Tau of $36,997 in the consolidated statement of comprehensive income (loss) for the year ended December 31, 2025. The fair value of Alpha Tau’s ordinary shares held by the Company was determined using the closing price of Alpha Tau’s ordinary shares on April 24, 2025 and December 31, 2025 of $2.612 and $4.95, respectively. On April 24, 2025 and December 31, 2025, the Company held approximately 17% of Alpha Tau’s ordinary shares’ voting interest.

The warrants issued under the Services Agreement are accounted for as a separate transaction from the Alpha Tau SPA. The fair value of the warrants is calculated based on Black-Scholes model.

Presented below is the summary of the assumptions and estimates that were used for the valuation of the Alpha Tau warrants as of June 23, 2025, the issuance date, and December 31, 2025:

	As of
Parameters and Assumptions	June 23, 2025			December 31, 2025
Share Price	$	2.985		$	4.95
Exercise Price		$ 3.47-3.9			$ 3.47-3.9
Expected Term		2.35			1.81
Volatility		55.61	%		49.04	%
Risk Free Rate		3.89	%		3.47	%
Dividend Rate		0	%		0	%

As of June 23, 2025, the issuance date, the fair value of the Alpha Tau warrants was $2,727. As of December 31, 2025, the fair value of the Alpha Tau warrants was $6,242. The change in fair value is recognized under “financial income (loss), net”.

Segment Reporting (Details)	12 Months Ended
Segment Reporting (Details)	Dec. 31, 2025 segment
Segment Reporting [Abstract]
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description	The Company’s Chief Executive Officer, serving as the Chief Operating Decision Maker (CODM), evaluates operational performance and makes resource allocation decisions based on net income (loss), which is reported in the consolidated statements of comprehensive income. The Company has determined that it operates in a single reportable segment, focused on research and development activities related to its proprietary products and technologies.
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]	Chief Executive Officer [Member]
Reportable segment	1

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2025	Mar. 26, 2026	Jun. 30, 2025
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Financial Statement Error Correction [Flag]	false
Entity Interactive Data Current	Yes
ICFR Auditor Attestation Flag	false
Amendment Flag	false
Document Period End Date	Dec. 31, 2025
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	FY
Documents Incorporated by Reference [Text Block]	None
Entity Information [Line Items]
Entity Registrant Name	ORAMED PHARMACEUTICALS INC.
Entity Central Index Key	0001176309
Entity File Number	001-35813
Entity Tax Identification Number	98-0376008
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Public Float			$ 77,659,391
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	1185 Avenue of the Americas
Entity Address, Address Line Two	Third Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10036
Entity Phone Fax Numbers [Line Items]
City Area Code	844
Local Phone Number	967-2633
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, par value $0.012
Trading Symbol	ORMP
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		40,446,179

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2025

Accounts Payable and Accrued Expenses [Abstract]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

NOTE 11 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES:

On December 25, 2025, the Company entered into a Simple Agreement for Future Equity (“SAFE”) with NINA Medical Ltd. (“Nina”), a privately-held company, pursuant to which the Company provided funding of $100 to Nina. Under the terms of the SAFE, the investor will be entitled to receive preferred shares of Nina in a future equity financing round or upon certain triggering events. The SAFE does not bear interest and has no maturity date.

Composition:

	December 31,
	2025		2024
Accounts payable	$	443	$	789
Payroll and related accruals		755		407
Income tax		3,286		3,204
Accrued liabilities – Legal Fee		1,084		402
Accrued liabilities – Other		633		338
	$	6,201	$	5,140

Financial Income (Loss), Net - Schedule of Financial Income (Loss), Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Schedule of Financial Income, Net [Line Items]
Financial Income (Loss), Net	$ 87,939	$ (7,416)
Interest Income	2,373	4,983
Exchange rate	(252)	174
Other	(606)	(27)
Revaluation of investments, net	89,454	(2,286)
Revaluation of Scilex, net [Member]
Schedule of Financial Income, Net [Line Items]
Financial Income (Loss), Net	44,647	(4,359)
Revaluation of Hapisga, net [Member]
Schedule of Financial Income, Net [Line Items]
Financial Income (Loss), Net	1,522
Revaluation of Alpha Tau, net [Member]
Schedule of Financial Income, Net [Line Items]
Financial Income (Loss), Net	36,997
Revaluation of RoyaltyVest loan, net [Member]
Schedule of Financial Income, Net [Line Items]
Financial Income (Loss), Net	(447)
Revaluation of Profit Sharing Loan Agreement [Member]
Schedule of Financial Income, Net [Line Items]
Financial Income (Loss), Net	372	57
Revaluation of Convertible Note [Member]
Schedule of Financial Income, Net [Line Items]
Financial Income (Loss), Net	1,636
Revaluation of other marketable securities [Member]
Schedule of Financial Income, Net [Line Items]
Financial Income (Loss), Net	$ 3,212	$ (3,114)

Marketable Securities (Details) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
Marketable Securities (Details) - USD ($) $ in Thousands	Nov. 11, 2025	Apr. 30, 2025	Dec. 31, 2025	Dec. 31, 2024	Jul. 01, 2025
Marketable Securities [Line Items]
Purchase shares (in Shares)			350,000
Aggregate purchase price	$ 8,501	$ 36,900
Percentage of transaction fees	1.00%
Expenses amount	$ 54		$ 238	$ 265
Securities Purchase Agreement [Member]
Marketable Securities [Line Items]
Invested amount					$ 1,500
Acquired shares (in Shares)					150,000
DNA [Member]
Marketable Securities [Line Items]
Unrealized gain (loss)			$ 116
Ownership percentage			0.20%
Entera [Member]
Marketable Securities [Line Items]
Unrealized gain (loss)			$ (21)
Ownership percentage			0.26%
Nano [Member]
Marketable Securities [Line Items]
Unrealized gain (loss)			$ (130)
Ownership percentage			2.58%
Pelthos [Member]
Marketable Securities [Line Items]
Unrealized gain (loss)			$ 3,150
Ownership percentage			4.90%
Common Stock [Member]
Marketable Securities [Line Items]
Gross proceed			$ 2,865
Purchase shares (in Shares)	5,436,791

Stock-Based Compensation

12 Months Ended

Dec. 31, 2025

Stock-Based Compensation [Abstract]

STOCK-BASED COMPENSATION

NOTE 15 - STOCK-BASED COMPENSATION:

The Company makes awards only under the 2019 Plan, under which, the Company had reserved a pool of 7,500,000 shares of the Company’s common stock which may be issued at the discretion of the board of directors from time to time. Under this 2019 Plan, each option or RSU is exercisable into one share of common stock of the Company. The options may be exercised after vesting and in accordance with vesting schedules which will be determined by the board of directors for each grant. The maximum term of the options and RSUs is 10 years.

The following are the significant stock options, RSUs transactions with employees and board members made during the years ended December 31, 2025 and 2024:

On January 4, 2024, the Company granted an aggregate of 941,500 RSUs representing a right to receive shares of the Company’s common stock to executive officers of the Company. The RSUs will vest in twelve equal quarterly installments starting January 8, 2024. The total fair value of these RSUs on the date of grant was $2,250 using the quoted closing market share price of $2.39 on the Nasdaq Capital Market on the date of grant.

On January 4, 2024, the Company granted 294,000 performance based RSUs (“PSUs”) representing a right to receive shares of the Company’s common stock to executive officers of the Company. The total amount of the PSUs shall vest upon the satisfaction of certain market conditions. The total fair value of these PSUs on the date of grant was $691, using the Monte-Carlo model, based on the quoted closing market share price of $2.39 on the Nasdaq Capital Market on the date of grant.

On January 4, 2024, the Company granted an aggregate of 187,610 RSUs representing a right to receive shares of the Company’s common stock to board members of the Company. 37,610 RSUs will vest in three equal quarterly installments starting April 1, 2024. 150,000 RSUs will vest in three equal annual installments starting January 1, 2025. The total fair value of these RSUs on the date of grant was $448, using the quoted closing market share price of $2.39 on the Nasdaq Capital Market on the date of grant.

On January 30, 2024, the Company granted an aggregate of 3,750 RSUs representing a right to receive shares of the Company’s common stock to board member of the Company. The RSUs will vest in four equal quarterly installments starting April 1, 2024. The total fair value of these RSUs on the date of grant was $11, using the quoted closing market share price of $2.98 on the Nasdaq Capital Market on the date of grant.

On April 17, 2024, the Company granted an aggregate of 29,800 RSUs representing a right to receive shares of the Company’s common stock to board member of the Company. 7,300 RSUs will vest in three equal quarterly installments starting July 1, 2024. 22,500 RSUs will vest in three equal annual installments starting January 1, 2025. The total fair value of these RSUs on the date of grant was $69, using the quoted closing market share price of $2.33 on the Nasdaq Capital Market on the date of grant.

On June 20, 2024, the Company granted 34,000 PSUs representing a right to receive shares of the Company’s common stock to the Company’s Chief Financial Officer. The total amount of the PSUs shall vest upon the later of (i) June 18, 2026 and (ii) satisfaction of certain market conditions. The total fair value of these PSUs on the date of grant was $73, using the Monte-Carlo model, based on the quoted closing market share price of $2.21 on the Nasdaq Capital Market on the date of grant.

On June 21, 2024, 140,040 RSUs representing a right to receive shares of the Company’s common stock were granted to executive officer. 93,360 shall vest in one installment on June, 18 2026 and 46,680 shall vest in four equal quarterly installments starting September 9, 2026. The total fair value of these RSUs on the date of grant was $305, using the quoted closing market share price of $2.18 on the Nasdaq Capital Market on the date of grant.

On November 11, 2024, the Company granted an aggregate of 135,000 RSUs representing a right to receive shares of the Company’s common stock to executive officers of the Company. The RSUs vested on the date of grant. The total fair value of these RSUs on the date of grant was $321, using the quoted closing market share price of $2.38 on the Nasdaq Capital Market on the date of grant.

On January 2, 2025, the Company granted 1,023,000 RSUs representing a right to receive shares of the Company’s common stock to the Company’s executive officers. The total amount of the RSUs shall vest in equal quarterly installments of approximately 85,249 over a three year period starting with the first quarterly vesting on January 1, 2025. The total fair value of these RSUs on the date of grant was $2,465 based on the quoted closing market share price of $2.41 on the Nasdaq Capital Market on the date of grant.

On January 2, 2025, the Company granted 328,500 PSUs representing a right to receive shares of the Company’s common stock to the Company’s executive officers. The total amount of the PSUs shall vest upon the satisfaction of certain performance conditions. The total fair value of these PSUs on the date of grant was $792 based on the quoted closing market share price of $2.41 on the Nasdaq Capital Market on the date of grant.

On January 2, 2025, the Board modified 294,000 outstanding PSUs that were granted to the Company’s executive officers adjusting the vesting criteria from market condition to performance targets. The incremental fair value arising from the modification was $13.

As of December 31, 2025, the PSUs granted to the Company’s executive officers were deemed to have achieved the first updated performance target. As a result, the Company recognized stock-based compensation expense of $197 for the year ended December 31, 2025, equal to the unrecognized grant-date fair value of the original award plus the incremental fair value arising from the modification.

On June 5, 2025, the Company granted an aggregate of 150,000 RSUs representing a right to receive shares of the Company’s common stock to the Company’s board members. The RSUs granted to the board members vest in three equal annual installments on each of January 1, 2026, 2027 and 2028. The total fair value of these RSUs on the date of grant was $323, using the quoted closing market share price of $2.15 on the Nasdaq Capital Market on the date of grant.

On June 5, 2025, the Company granted an aggregate of 34,876 RSUs representing a right to receive shares of the Company’s common stock to the Company’s board members. The RSUs granted to certain board members vest in four monthly installments on each of June 5, 2025, July 1, 2025, October 1, 2025 and January 1, 2026. The total fair value of these RSUs on the date of grant was $75, using the quoted closing market share price of $2.15 on the Nasdaq Capital Market on the date of grant.

On December 31, 2025, the Company granted an aggregate of 20,900 RSUs representing a right to receive shares of the Company’s common stock to the Company’s board members. The RSUs granted to the board members vest in four equal quarterly installments starting April 1, 2026. The total fair value of these RSUs on the date of grant was $60, using the quoted closing market share price of $2.85 on the Nasdaq Capital Market on the date of grant.

On December 31, 2025, the Company granted an aggregate of 120,000 RSUs representing a right to receive shares of the Company’s common stock to the Company’s board members. The RSUs granted to certain board members vest in three equal annual installments on each of January 1, 2027, 2028 and 2029. The total fair value of these RSUs on the date of grant was $342, using the quoted closing market share price of $2.85 on the Nasdaq Capital Market on the date of grant.

On December 31, 2025, the Company granted an aggregate of 616,000 RSUs representing a right to receive shares of the Company’s common stock to executive officers of the Company. The RSUs will vest in eleven equal quarterly installments starting April 1, 2026. The total fair value of these RSUs on the date of grant was $1,756 using the quoted closing market share price of $2.85 on the Nasdaq Capital Market on the date of grant.

On December 31, 2025, the Company granted an aggregate of 588,514 RSUs representing a right to receive shares of the Company’s common stock to executive officers of the Company. The RSUs vested on January 1, 2026. The total fair value of these RSUs on the date of grant was $1,677, using the quoted closing market share price of $2.85 on the Nasdaq Capital Market on the date of grant.

On December 31, 2025, the Company granted 166,000 PSUs representing a right to receive shares of the Company’s common stock to executive officers of the Company. The PSUs vest upon the satisfaction of certain performance conditions. The total fair value of these PSUs on the date of grant was $472, using the quoted closing market share price of $2.85 on the Nasdaq Capital Market on the date of grant.

On December 31, 2025, the Company granted 166,000 PSUs representing a right to receive shares of the Company’s common stock to executive officers of the Company. The PSUs vest upon the satisfaction of certain performance conditions or certain market conditions. The total fair value of these PSUs on the date of grant was $473, using the quoted closing market share price of $2.85 on the Nasdaq Capital Market on the date of grant. See additional information in note 21(c).

Options to employees, directors and non-employees

A summary of the status of the stock options granted to employees and directors as of December 31, 2025 and 2024 and changes during the years ended on those dates, is presented below:

	Year ended December 31,
	2025					2024
	Number of options			Weighted average exercise price		Number of options			Weighted average exercise price
				$					$
Options outstanding at beginning of year		1,661,008			7.21		1,909,676			8.03
Changes during the year:
Granted		-			-		-			-
Forfeited		(625	)		13.89		(49,125	)		13.92
Expired		-			-		(199,543	)		13.40
Exercised		-			-		-			-
Options outstanding at end of year		1,660,383			7.21		1,661,008			7.21
Options exercisable at end of year		1,501,633			7.18		1,442,258			6.91

Expenses recognized in respect of stock options granted to employees and directors, for the years Ended December 31, 2025 and 2024, were $89 and $213, respectively.

Options to employees, directors and non-employees

The following table presents summary information concerning the options granted to employees and directors outstanding as of December 31, 2025:

Exercise prices $	Number outstanding		Weighted Average Remaining Contractual Life Years		Weighted average exercise price $
1-6		840,500		3.83		3.94
6.23-9.12		283,008		1.80		7.96
10.40-20.19		536,875		5.50		11.94
		1,660,383		4.02		7.21

As of December 31, 2025, there were no unrecognized compensation costs related to non-vested options previously granted to employees and directors.

47,000 options granted to non-employees were outstanding and exercisable as of December 31, 2025 and 2024. The Company recorded no stock-based compensation related to non-employees’ awards during the years ended December 31, 2025 and 2024. During the years ended December 31, 2025 and 2024, no options were exercised.

As of December 31, 2025, there were no unrecognized compensation costs related to non-vested options previously granted to non-employees.

Options to employees, directors and non-employees

The following table presents summary information concerning the options granted to non-employees outstanding as of December 31, 2025:

Range of exercise prices $		Number outstanding				Weighted Average Remaining Contractual Life Years				Weighted Average Exercise Price $
3.74-5.08			47,000				3.98				4.31

Restricted stock units

The following table summarizes the activities for unvested RSUs and PSUs granted to employees and directors for the years ended December 31, 2025 and 2024:

	Year ended December 31,
	2025			2024
	Number of RSUs
Outstanding at the beginning of year		2,572,065			1,834,362
Changes during the year:
Granted		3,228,791			1,792,460
Issued		(1,410,437	)		(617,542	)
Forfeited		(6,925	)		(386,445	)
Expired		-			(50,770	)
Outstanding at the end of the year		4,383,494			2,572,065
Vested during the year		1,880,104			925,937
Vested and unissued at year end		952,928			483,261

The Company recorded compensation expenses related to RSUs and PSUs of $5,063 for the year ended December 31, 2025 and $3,787 for the year ended December 31, 2024.

As of December 31, 2025, there were unrecognized compensation costs of $5,041 related to RSUs and PSUs. The unrecognized compensation costs are expected to be recognized over a weighted average period of 0.72 year.

The Company recorded total compensation expenses of $5,152 and $4,053 for the years ended December 31, 2025 and 2024, respectively. $1,893 and $1,998 were included in Research and Development expenses, $3,259 and $2,055 were included in General and Administrative expenses for the years ended December 31, 2025 and 2024, respectively.

Commitments (Tables)

12 Months Ended

Dec. 31, 2025

Commitments [Abstract]

Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities

Below is a summary of the Company’s operating right-of-use assets and operating lease liabilities as of December 31, 2025 and 2024:

	December 31, 2025			December 31, 2024
Operating right-of-use assets	$	750		$	414

Operating lease liabilities, current		285			216
Operating lease liabilities long-term		540			156
Total operating lease liabilities	$	825		$	372

Weighted Average of Remaining Lease Term
Operating leases		3.76			1.8

Weighted Average Discount Rate
Operating leases		6.3	%		3.52	%

Schedule of Right-of-Use Assets Over the Remaining Lease

Lease payments for the Company’s right-of-use assets over the remaining lease periods as of December 31, 2025 are as follows:

	December 31, 2025

2026	$	332
2027		192
2028		163
2029		157
2030		104
Total undiscounted lease payments		948
Less: Interest*		(123	)
Present value of lease liabilities	$	825

*	Future lease payments were discounted by 3%-7% interest rate.

Financial Income (Loss), Net (Tables)

12 Months Ended

Dec. 31, 2025

Financial Income (Loss), Net [Abstract]

Schedule of Financial Income (Loss), Net

	Year ended December 31,
	2025			2024
Revaluation of investments, net:
Revaluation of Scilex, net (see note 4)		44,647			(4,359	)
Revaluation of Hapisga, net (see note 7)		1,522			-
Revaluation of Alpha Tau, net (see note 8)		36,997			-
Revaluation of RoyaltyVest loan, net (see note 4)		(447	)		-
Revaluation of Profit Sharing Loan Agreement (see note 4)		372			57
Revaluation of Convertible Note (see note 9)		1,636			-
Revaluation of other marketable securities (see note 4)		3,212			(3,114	)
		87,939			(7,416	)
Interest Income		2,373			4,983
Exchange rate		(252	)		174
Other		(606	)		(27	)
	$	89,454		$	(2,286	)

Related Party Transactions (Details) ₪ in Thousands, $ in Thousands	Jan. 01, 2026 USD ($)	Jan. 01, 2026 ILS (₪)	Apr. 01, 2025 USD ($)	Apr. 01, 2025 ILS (₪)	Jul. 01, 2024 USD ($)	Jul. 01, 2024 ILS (₪)	Jan. 01, 2024 USD ($)	Jan. 01, 2024 ILS (₪)
Chief Scientific Officer [Member]
Related Party Transactions [Line Items]
Consulting fee paid	$ 22	₪ 71,648
Officer gross monthly salary	17	55,114
Chief Scientific Officer [Member] \| KNRY [Member]
Related Party Transactions [Line Items]
Consulting fee paid			$ 20	₪ 67,275	$ 40	₪ 134,550
President [Member]
Related Party Transactions [Line Items]
Consulting fee paid							$ 34	₪ 111,349
Officer gross monthly salary			$ 16	₪ 51,750			$ 18	₪ 59,330
Subsequent Event [Member]
Related Party Transactions [Line Items]
Officer gross monthly salary	20	63,186
Subsequent Event [Member] \| Chief Executive Officer [Member]
Related Party Transactions [Line Items]
Consulting fee	$ 37	₪ 118,587

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

+ Details

Short-Term Borrowings

12 Months Ended

Dec. 31, 2025

Short-Term Borrowings [Abstract]

SHORT-TERM BORROWINGS

NOTE 12 - SHORT-TERM BORROWINGS:

On August 8, 2023, the Company borrowed an aggregate of $99,550 pursuant to loan agreements from Israel Discount Bank Ltd. (the “Short-Term Borrowings”). The Short-Term Borrowings had maturity dates ranging from August 11, 2023 to May 24, 2024, bore interest ranging from 6.66% to 7.38%, and were secured by certificates of deposits issued by Israel Discount Bank Ltd. having an aggregate face amount of $99,550. The net proceeds of the Short-Term Borrowings were used to fund the Tranche A Note (for further details, see note 4). The Short-Term Borrowings were paid in one payment of principal and interest at each respective maturity. As of December 31, 2024, the Company repaid the entire Short-Term Borrowings amount .

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Investments, at Fair Value

12 Months Ended

Dec. 31, 2025

Investments, at Fair Value [Abstract]

INVESTMENTS, AT FAIR VALUE

NOTE 4 - INVESTMENTS, AT FAIR VALUE:

2023 Scilex Transaction and 2024 Refinancing

On April 14, 2025, Scilex effected a 1-for-35 reverse stock split of its issued and outstanding common stock (“Reverse Split”). As a result, every 35 shares of Scilex common stock were automatically reclassified into 1 share of common stock, with fractional shares rounded up to the nearest whole share. Unless otherwise indicated, all share numbers presented below reflect the effect of the Reverse Split. The 6,500,000 Subsequent Penny Warrants (as defined below) that were outstanding as of the Reverse Split date, were not subject to adjustment under the Reverse Split.

2023 Scilex Transaction

On September 21, 2023, the Company entered into and consummated the transactions (collectively, the “2023 Scilex Transaction”) contemplated by a securities purchase agreement with Scilex, pursuant to which Scilex issued to the Company:

A senior secured promissory note (the “Tranche A Note”), with a principal amount of $101,875, initially maturing on March 21, 2025 and bearing interest of SOFR plus 8.5%, payable in-kind. Scheduled principal payments were due quarterly from December 21, 2023, through December 21, 2024, with the remaining balance due on March 21, 2025. The maturity was subsequently extended to December 31, 2025, in exchange for 92,858 shares of Scilex common stock. An exit fee of $3,056 became payable when the note was not repaid by March 21, 2024. Following the Option Agreement (as defined below), the maturity was subsequently extended to March 31, 2026.

As of December 31, 2025, Scilex had repaid $69,200 of the amount due under the Tranche A Note and refinanced $25,000 as part of the 2024 Refinancing (as defined below). As of March 26, 2026, the outstanding principal balance of the Tranche A Note is $7,675 and accrued interest totaled $17,153.

The Tranche A Note constitutes senior secured indebtedness of Scilex and is guaranteed by all existing or future formed, direct and indirect, domestic subsidiaries of Scilex and is secured by a first priority security interest and liens on all of the assets of Scilex, subject to customary and mutually agreed permitted liens and except for certain specified exemptions.

Warrants to purchase up to 128,572 shares of Scilex common stock with an exercise price of $0.35 per share (the “Closing Penny Warrants”) and additional warrants (the “Subsequent Penny Warrants”) to purchase up to 57,143 shares of Scilex common stock (after giving effect to the Reverse Split) and warrants to purchase up to 6,500,000 shares of Scilex common stock (which such amount was not adjusted for the Reverse Split pursuant to the terms of such warrants) with an exercise price of $0.35 and $0.01 per share, respectively.

During 2024, the Company exercised 128,572 Closing Penny Warrants and 57,143 Subsequent Penny Warrants.

On July 22, 2025, the Company entered into an option agreement (the “Option Agreement”) with Scilex, granting Scilex the right to repurchase the Company remaining 6,500,000 Subsequent Penny Warrants for $27,000 plus a $1,500 fee. In two separate installments on September 30, 2025 and December 30, 2025, Scilex exercised its right under the Option Agreement and repurchased all of the subject warrants for total proceeds to the Company of $ 28,500 (including the option fee). As of December 31, 2025, the Company does not hold any Subsequent Penny Warrants.

Transferred warrants (the “Transferred Warrants”) to purchase 114,286 shares of Scilex common stock with an exercise price of $402.50 per share, fully exercisable and expiring on November 10, 2027. On September 20, 2024, the Company sold the Transferred Warrants for $300. As of December 31, 2025, the Company no longer held any Transferred Warrants.

The Company selected the fair value option for the Tranche A Note and the Penny Warrants in order to reduce operational complexity of bifurcating embedded derivatives. Changes in value are recorded under financial income (loss), net and include interest income on the Tranche A Note.

The valuation was performed based on several scenarios. Each scenario took into consideration the present value of the Tranche A Note’s cash flows and the Warrants’ value. The total value of the 2023 Scilex Transaction (and of each of its components) was valued on a weighted average of the different scenarios.

The discount rate of the Tranche A Note was based on the B- rating zero curve in addition to a risk premium which takes into account the credit risk of Scilex and ranged between 111.86 % to 111.78%.

The table below represents the fair value composition of the Tranche A Note:

	December 31, 2025		December 31, 2024
Tranche A Note	$	23,063	$	13,714
Subsequent Penny Warrants	$	-	$	2,772
Total	$	23,063	$	16,486

As of December 31, 2025 and December 31, 2024, the Tranche A Note is included under Investments at fair value, current assets.

As of December 31, 2025, and December 31, 2024, the fair value of the Tranche A Note was less than the aggregate unpaid principal balance (which includes interest payable on maturity) by $1,765 and $8,114, respectively.

2024 Refinancing

In October 2024, the Company entered into the transactions (collectively, the “2024 Refinancing”) pursuant to which Scilex issued to the Company:

a. Convertible Notes SPA

The Company entered into a securities purchase agreement (the “Convertible Notes SPA”) with the other Tranche Note B holders (together with the Company, the “Buyers”) and Scilex to refinance a portion of the Tranche A Note and pay off certain other indebtedness of Scilex. Pursuant to the Convertible Notes SPA, the Buyers purchased in a registered offering by Scilex (i) a new tranche B of senior secured convertible notes of Scilex in the aggregate principal amount of $50,000 (the “Tranche B Note”) repayable on a quarterly basis for 2 years, which Tranche B Note is convertible into shares of Scilex common stock and (ii) warrants to purchase up to 214,286 shares of Scilex common stock with an exercise price of $36.4 (the “Tranche B Warrants”). The Company purchased 50% of the Tranche B Note and the Tranche B Warrants, equal to an aggregate principal amount of $25,000 of the Tranche B Note and 107,143 Tranche B Warrants.

Scilex received from the Company, in consideration of the Tranche B Note and the Tranche B Warrants issued to the Company, an exchange and reduction of the principal outstanding balance under the Tranche A Note of $22,500.

As of December 31, 2025, Scilex has repaid $9,875 of the principal amount outstanding under the Tranche B Note, leaving a remaining principal balance of $15,125 with accrued interest of $495. The Tranche B Note matures on October 8, 2026.

b. Royalty Purchase Agreement

The Company and the other Tranche Note B holders (together with the Company, the “RPA Purchasers”) entered into a Purchase and Sale Agreement (the “Royalty Purchase Agreement”) with Scilex and Scilex Pharmaceuticals Inc. (“Scilex Pharma”). Pursuant to the Royalty Purchase Agreement, the RPA Purchasers acquired the right to receive, in the aggregate, 8% of net sales worldwide for 10 years (the “Purchased Receivables”) with respect to ZTLido (lidocaine topical system) 1.8%, SP-103 (lidocaine topical system) 5.4%, and any related, improved, successor, replacement or varying dosage forms of the foregoing. The Company acquired the right to receive 50% of the Purchased Receivables and therefore holds the right to receive 4% royalties.

In consideration for its interest in the Purchased Receivables, the Company exchanged and reduced $2,500 of the principal balance under the Tranche A Note.

c. ZTlido Rest of the World Binding Agreement

The Company and certain other institutional investors and Scilex entered into a binding term sheet (“ROW License Term Sheet”), regarding a license and development agreement, with respect to services, compositions, products, dosages and formulations comprising lidocaine, including without limitation, the product and any future product defined as a “Product” under Scilex Pharma’s existing (i) Product development agreement, dated as of May 11, 2011, with Oishi Koseido Co., Ltd. (“Oishi”), and Itochu Chemical Frontier Corporation (“Itochu”), as amended, and (ii) the associated commercial supply agreement, dated February 16, 2017, between Scilex, Oishi and Itochu, as amended.

The Company and such institutional investors hold this license through RoyaltyVest. See note 6 for additional information about RoyaltyVest.

The institutional investors who are parties to the Convertible Notes SPA, Royalty Purchase Agreement and the ZTLido License Agreement are all inter-related.

d. Tranche B Note Consent

On January 2, 2025, the Company and other Tranche B Note holders entered into deferral and consent agreements with Scilex (the “Tranche B Consent”), deferring Scilex’s first amortization payment under the Tranche B Note to October 8, 2026. In consideration, the Company received $877 ($500 of the principal amount and $377 of accrued interest), and 71,429 shares of Scilex common stock.

As part of the Tranche B Consent and contingent upon certain conditions that were met:

●

Scilex and the Tranche B Note holders agreed to a 10-year, assignable 4% royalty on global net sales of Gloperba and Elyxyb, excluding Elyxyb sales in Canada, with the Company entitled to 2%. Gloperba, an oral liquid colchicine formulation for gout, and Elyxyb, an oral solution for acute migraine treatment, represent key assets in Scilex’s portfolio. The definitive agreement was signed on February 28, 2025.

●

The Tranche B Note holders had the option, through RoyaltyVest, to fund up to 50% of the cash purchase price for Ex-U.S. product rights to Gloperba and Elyxyb (excluding Elyxyb in Canada) and will receive proportional revenues from commercialization and licensing. As of December 31, 2025, RoyaltyVest exercised its option to Ex-U.S. product rights of Gloperba for $500. See note 6 for further details.

e. Warrant Agreement

In October 2025, the Company agreed to defer an amortization payment due from Scilex on October 1, 2025 under the amortization schedule included in the Tranche B Notes. The deferred amortization payment was subsequently paid to us in November 2025. In consideration for this deferral, Scilex agreed to issue to the Company warrants to purchase 100,000 shares of Scilex’s common stock, par value $0.0001 per share with an exercise price of $20. The warrants were issued on February 19, 2026.

The Company elected the fair value option for the Tranche B Note and the Royalty Purchase Agreement, the Note B Warrants meet the definition of a derivative and therefore will be measured at fair value. Changes in value are recorded under financial income (loss), net and include interest income on the Tranche B Note.

The valuation of the Tranche B Note’s was performed based on the binomial model, using a discount rate of 111.89%. Presented below is the summary of the assumptions and estimates that were used for the valuation as of December 31, 2025:

Parameters and Assumptions
Share Price	$	12.20
Conversion Rate		36.40
Floor Rate		36.40
Expected Term		0.77
Volatility		66.39	%
Risk Free Rate		3.44	%
Yield		75.09	%

The fair value of the Note B Warrants was calculated based on Black and Scholes model.

Presented below is the summary of the assumptions and estimates that were used for the valuation of the Warrants as of December 31, 2025:

Parameters and Assumptions
Share Price	$	12.20
Exercise Price	$	20 – 36.4
Expected Term		3.77 – 3.95
Volatility		68.63 – 68.27	%
Risk Free Rate		3.57 – 3.58	%
Dividend Rate		0	%

The value of the Royalty Purchase Agreement was calculated according to the royalty payment schedule and the aggregation of discounted cash flows derived from the royalty payments, using a discount rate of between 111.51% to 111.83%.

As of December 31, 2025, and December 31, 2024, the fair value of the Tranche B Note was less than the aggregate unpaid principal balance (which includes interest payable on maturity) by $4,488 and $9,833, respectively.

The table below represents the fair value composition of the Tranche B Note:

	December 31, 2025						December 31, 2024
	Short term		Long term		Total		Short term		Long term		Total
Tranche Note B	$	11,473	$	-	$	11,473	$	11,263	$	4,535	$	15,798
Warrant	$	-	$	850	$	850	$	-	$	548	$	548
Royalty Purchase Agreement	$	1,072	$	1,137	$	2,209	$	1,039	$	937	$	1,976
Total	$	12,545	$	1,987	$	14,532	$	12,302	$	6,020	$	18,322

Scilex Transaction Summary

The table below represents the fair value cycle of 2023 Scilex Transaction and 2024 Refinancing Transaction throughout December 31, 2024 and December 31, 2025:

	Tranche A			Tranche B			Total
Balance as of December 31, 2023	$	110,188			-		$	110,188
2024 Refinancing		(21,575	)		25,000			3,425
Proceeds from the sale of Transferred Warrants		(300	)		-			(300	)
Cash received from Tranche A Note repayment		(64,200	)		-			(64,200	)
Exercised warrants (*)		(6,123	)		-			(6,123	)
Amounts receivable from the royalty agreement		-			(398	)		(398	)
Change in fair value		(1,504	)		(6,280	)		(7,784	)
Balance as of December 31, 2024		16,486			18,322			34,808
Amounts receivable from the royalty agreement (**)		-			(1,640	)		(1,640	)
Principal payments					(9,875	)		(9,875	)
Proceeds from the sale of Subsequent Penny Warrants		(28,500	)		-			(28,500	)
Interest payments					(1,845	)		(1,845	)
Change in fair value		35,077			9,570			44,647
Balance as of December 31, 2025	$	23,063		$	14,532		$	37,595

(*)

(**)	As of December 31, 2025, out of this amount $449 is included under prepaid expenses and other current assets.

Financial income (loss) recognized in respect of the 2023 Scilex Transaction and the 2024 Refinancing, for the years ended December 31, 2025 and 2024, were $44,647 and ($4,359), respectively.

The table below represents the fair value breakdown as of December 31, 2025:

	Tranche A Note						Tranche B Note						Total
	Amount		Accrued Interest		Fair Value		Amount		Accrued Interest		Fair Value		Fair Value
Notes	$	7,675	$	17,153	$	23,063	$	15,125	$	341	$	11,473	$	34,536
Warrants		-		-		-		207,143		-	$	850	$	850
Royalty Purchase Agreement payment		-		-		-		-		-	$	2,209	$	2,209
December 31, 2025					$	23,063				-	$	14,532	$	37,595

During the year ended December 31, 2025, the Company sold 350,000 shares of common stock of Scilex. As of December 31, 2025, the Company no longer holds any shares of Scilex common stock.

All Scilex securities described above are subject to a beneficial ownership limitation, which restricts the Company’s holdings to a maximum of 9.99% of Scilex’s outstanding shares at any time.

Profit Sharing Loan Agreement

On September 4, 2024, the Company entered into a loan agreement (the “Profit Sharing Loan Agreement”) with Rabi Binyamin 4 Tama 38 Ltd. (the “Borrower”) to finance a real estate project (the “Project”). According to the terms of the Profit Sharing Loan Agreement, Oramed agreed to loan NIS 5.5 million ($1,523) (the “Loan Principal”) to the Borrower. NIS 4.7 million ($1,307) was loaned upon signing the Profit Sharing Loan Agreement and an additional NIS 0.8 million ($237) will be loaned upon achievement of certain milestones. On October 28, 2025, the Borrower met the milestones and became entitled to the additional payment.

Upon completion of the Project, the Company is entitled to receive the Loan Principal and the greater of: (i) 20% annual interest of the Loan Principal and (ii) 40% of the Project profits.

On September 14, 2025, the Company loaned an additional NIS 0.5 million ($150) to the Borrower (“Additional Loan”). The Additional Loan bears an annual interest of 6% and shall be repaid by December 31, 2025. According to the Additional Loan agreement, the Company shall be entitled to instruct the Borrower that instead of repaying the Additional Loan on the maturity date, the principal amount of the loan, as well as any accrued interest up to the date of such notice, shall be deemed to constitute a loan amount provided by the Company, as part of the remaining portion of the Profit-Sharing Loan Agreement. As of December 31, 2025 the Additional Loan had not been repaid. The maturity date of the Additional Loan was subsequently extended to June 30, 2026.

The Company decided to designate the Profit Sharing Loan Agreement as a whole under the Fair-Value option in accordance with Accounting Standards Codification (“ASC”) Topic 825 “Financial Instruments”. The valuation of the Profit Sharing Loan Agreement was based on various project profit scenarios. The Company used the Wang Transform model, a risk-neutral probabilities method, with an expected term of 2.67 years, a curve rate of 16.32% and a risk spread of 0.43%. The value of the Profit Sharing Loan Agreement and the Additional Loan as of December 31, 2025 was $1,890.

Convertible Secured Promissory Note - Schedule of Assumptions and Estimates that Were Used for the Valuation (Details) - Binomial Model [Member]	12 Months Ended
	Dec. 31, 2025
Share Price [Member]
Schedule of Secured Promissory Note Assumptions and Estimates that Used for the Valuation [Line Items]
Convertible notes measurement input	0.58
Conversion Rate [Member]
Schedule of Secured Promissory Note Assumptions and Estimates that Used for the Valuation [Line Items]
Convertible notes measurement input	0.45
Maturity Date [Member]
Schedule of Secured Promissory Note Assumptions and Estimates that Used for the Valuation [Line Items]
Convertible notes measurement input description	May 14, 2026
Volatility [Member]
Schedule of Secured Promissory Note Assumptions and Estimates that Used for the Valuation [Line Items]
Convertible notes measurement input	113.38
Risk Free Rate [Member]
Schedule of Secured Promissory Note Assumptions and Estimates that Used for the Valuation [Line Items]
Convertible notes measurement input	3.3
Yield [Member]
Schedule of Secured Promissory Note Assumptions and Estimates that Used for the Valuation [Line Items]
Convertible notes measurement input	27.76

Taxes on Income (Details) - USD ($) $ in Thousands	12 Months Ended
Taxes on Income (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Taxes on Income [Line Items]
Corporate tax rate	21.00%	21.00%
Percentage of taxable income	80.00%
Corporate taxation term	20 years
Cash paid for income tax	$ 3,318	$ 0
Unrecognized tax expenses	12 months
Tax Jurisdiction of Domicile [Extensible Enumeration]	federal	federal
Oravax Medical Inc. [Member]
Taxes on Income [Line Items]
Accumulated tax loss carryforward	$ 3,395	$ 3,386
Israel Tax Authority [Member]
Taxes on Income [Line Items]
Corporate tax rate	23.00%	23.00%
Accumulated tax loss carryforward	$ 115,623	$ 113,419

Taxes on Income - Schedule of Assuming all Income is Taxed at Regular Tax Rates Applicable to Companies in United States, and Actual Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Schedule of Assuming all Income is Taxed at Regular Tax Rates Applicable to Companies in United States, and Actual Tax Expense [Abstract]
Income (loss) before taxes expenses, value	$ 75,324	$ (15,920)
Statutory tax (benefit) expense, value	$ 15,818	$ (3,343)
Statutory tax (benefit) expense, Percentage	21.00%	21.00%
Israel
Share-based payment awards, value	$ 2,573
Share-based payment awards, percenatge	3.40%
Change in valuation allowance, value	$ (1,137)
Change in the valuation allowance, Percentage	(1.50%)
Statutory tax rate difference between Israel and United States, value	$ 579
Statutory tax rate difference between Israel and United States, percentage	0.80%
Other, value	$ 13
Other, percentage	0.00%
Effect of cross-border tax laws, value	$ 114
Effect of cross-border tax laws, percentage	0.20%
Nontaxable or nondeductible items, value	$ 122
Nontaxable or nondeductible items, percentage	0.20%
Other, value	$ (174)
Other, percentage	(0.20%)
Increase (decrease) in income taxes resulting from:
Change in valuation allowance, value	$ (6,600)	$ 7,647
Change in the valuation allowance, Percentage	(8.80%)
Disallowable deductions, value		(878)
Influence of different tax rate applicable to the Subsidiary and Oravax Medical Ltd., value		(219)
Prior year adjustments, value		(13)
Uncertain tax position, value		(11)
Taxes on income for the reported year, value	$ 11,308	$ 3,183
Taxes on income for the reported year, Percentage	15.00%

Investments, at Fair Value (Details)
$ / shares in Units, $ in Thousands, ₪ in Millions

12 Months Ended

Nov. 11, 2025

Oct. 30, 2025

USD ($)

$ / shares

Jul. 22, 2025

USD ($)

Apr. 14, 2025

Mar. 04, 2025

$ / shares

Jan. 02, 2025

USD ($)

Oct. 30, 2024

Sep. 20, 2024

USD ($)

Sep. 04, 2024

USD ($)

Sep. 21, 2023

USD ($)

Dec. 31, 2025

USD ($)

$ / shares

Dec. 31, 2024

USD ($)

$ / shares

Dec. 30, 2025

USD ($)

Sep. 30, 2025

USD ($)

Sep. 14, 2025

USD ($)

Sep. 14, 2025

ILS (₪)

Sep. 04, 2024

ILS (₪)

Investments, at Fair Value [Line Items]

Reverse stock split

1-for-35

12-for-1

Common stock shares (in Shares) | shares

39,275,006

39,919,545

Exchange of shares (in Shares) | shares

92,858

Repaid amount

$ 49,550

Warrants to purchase shares (in Shares) | shares

100,000

20,000

Warrant per share (in Dollars per share) | $ / shares

$ 0.001

$ 0.35

Exercise price (in Dollars per share) | $ / shares

$ 4.13

Shares of common stock (in Shares) | shares

6,500,000

71,429

Warrants fee

$ 1,500

Total proceeds for warrants

$ 10,119

$ 7,387

Warrants to purchase shares (in Shares) | shares

114,286

Fair value and aggregate unpaid principal balance

$ 4,488

$ 9,833

Repayable quarterly basis period

2 years

Percentage of net sales

8.00%

Net sales worldwide period

10 years

Percentage of purchased receivables

50.00%

Percentage of right to receive royalties

4.00%

Principal balance

$ 2,500

Received amount

$ 877

Term of net sales

10 years

Percentage of cash purchase price

50.00%

Vest exercised amount

$ 500

Par value (in Dollars per share) | $ / shares

$ 0.0001

$ 0.012

Exercise price amount

^[1]

$ 6,123

Prepaid expenses

$ 449

Financial income (expenses)

$ (606)

$ (27)

Sold shares (in Shares) | shares

350,000

Percentage of beneficial ownership

9.99%

Percentage of project profits

40.00%

Additional loan

$ 1,890

2023 Scilex Transaction [Member]

Investments, at Fair Value [Line Items]

Principal of note issued

$ 101,875

Maturity date

Mar. 21, 2025

Interest bearing percentage

8.50%

Profit Sharing Loan Agreement [Member]

Investments, at Fair Value [Line Items]

Percentage of annual interest of loan principal

20.00%

Loan [Member]

Investments, at Fair Value [Line Items]

Percentage of annual interest of loan principal

6.00%

Additional loan

$ 150

₪ 0.5

Closing Penny Warrant [Member]

Investments, at Fair Value [Line Items]

Warrants shares (in Shares) | shares

128,572

Common Stock [Member]

Investments, at Fair Value [Line Items]

Exercise price (in Dollars per share) | $ / shares

$ 6,500,000

Subsequent Penny Warrants [Member]

Investments, at Fair Value [Line Items]

Exercisable warrants (in Shares) | shares

27,000

57,143

Tranche B Warrants [Member]

Investments, at Fair Value [Line Items]

Warrants to purchase shares (in Shares) | shares

214,286

Warrant per share (in Dollars per share) | $ / shares

$ 36.4

Aggregate principal amount

$ 25,000

Percentage of tranche purchased

50.00%

Tranche B warrants (in Shares) | shares

107,143

Tranche A Note [Member]

Investments, at Fair Value [Line Items]

Principal outstanding balance

$ 22,500

Tranche B Note Consent [Member]

Investments, at Fair Value [Line Items]

Accrued interest

377

Principal amount

$ 500

Tranche B Note [Member]

Investments, at Fair Value [Line Items]

Percentage of net sales

2.00%

Warrant [Member]

Investments, at Fair Value [Line Items]

Exercise price amount

$ 20

Tranche B [Member]

Investments, at Fair Value [Line Items]

Aggregate principal amount

$ 50,000

Percentage of discount rate

111.89%

Royalty Purchase Agreement [Member]

Investments, at Fair Value [Line Items]

Percentage of net sales

5.40%

Expected Term [Member] | Loan [Member]

Investments, at Fair Value [Line Items]

Risk-neutral probabilities method, measurement input

2.67

Curve Rate [Member] | Profit Sharing Loan Agreement [Member]

Investments, at Fair Value [Line Items]

Risk-neutral probabilities method, measurement input

16.32

Risk Spread [Member] | Profit Sharing Loan Agreement [Member]

Investments, at Fair Value [Line Items]

Risk-neutral probabilities method, measurement input

0.43

Common Stock [Member]

Investments, at Fair Value [Line Items]

Common stock shares (in Shares) | shares

Warrants to purchase shares (in Shares) | shares

185,715

Warrant per share (in Dollars per share) | $ / shares

$ 0.35

Sold shares (in Shares) | shares

5,436,791

Extension Agreement [Member] | Closing Penny Warrant [Member]

Investments, at Fair Value [Line Items]

Exercisable warrants (in Shares) | shares

6,500,000

Scilex [Member]

Investments, at Fair Value [Line Items]

Repaid amount

$ 9,875

Exercisable price per share (in Dollars per share) | $ / shares

$ 402.5

Expiring date

Nov. 10, 2027

Amount on consideration

$ 300

Remaining principal balance

$ 15,125

Accrued interest

495

Financial income (expenses)

$ 44,647

$ 4,359

Scilex Common Stock [Member]

Investments, at Fair Value [Line Items]

Warrants to purchase shares (in Shares) | shares

57,143

Gloperba and Elyxyb [Member]

Investments, at Fair Value [Line Items]

Percentage of net sales

4.00%

Loan Agreement [Member]

Investments, at Fair Value [Line Items]

Loan principal

$ 1,523

₪ 5.5

Profit Sharing Loan Agreement [Member]

Investments, at Fair Value [Line Items]

Loan principal

1,307

4.7

Additional loan Agreement [Member]

Investments, at Fair Value [Line Items]

Loan principal

$ 237

₪ 0.8

2023 Scilex Transaction [Member]

Investments, at Fair Value [Line Items]

Exit fee

$ 3,056

Refinanced amount

25,000

Principal outstanding balance

7,675

Accrued interest

17,153

2023 Scilex Transaction [Member] | Scilex [Member]

Investments, at Fair Value [Line Items]

Repaid amount

$ 69,200

Scilex Transaction [Member] | Penny Warrants [Member]

Investments, at Fair Value [Line Items]

Warrants to purchase shares (in Shares) | shares

128,572

Scilex Transaction [Member] | Subsequent Penny Warrants [Member]

Investments, at Fair Value [Line Items]

Total proceeds for warrants

$ 28,500

Scilex Transaction [Member] | Scilex Holding Company [Member] | Penny Warrants [Member]

Investments, at Fair Value [Line Items]

Warrant per share (in Dollars per share) | $ / shares

$ 0.01

Tranche A Note [Member]

Investments, at Fair Value [Line Items]

Fair value and aggregate unpaid principal balance

$ 1,765

$ 8,114

Lidocaine Topical System [Member]

Investments, at Fair Value [Line Items]

Percentage of net sales

1.80%

Minimum [Member]

Investments, at Fair Value [Line Items]

Discount rate

111.86%

Percentage of discount rate

111.51%

Maximum [Member]

Investments, at Fair Value [Line Items]

Discount rate

111.78%

Percentage of discount rate

111.83%

[1]

Accounts Payable and Accrued Expenses (Details) $ in Thousands	Dec. 25, 2025 USD ($)
NINA Medical Ltd. [Member]
Accounts Payable and Accrued Expenses (Details) [Line Items]
Company funding, amount	$ 100

Investments, at Fair Value - Schedule of Assumptions and Estimates Valuation (Details)	Dec. 31, 2025
Share Price [Member] \| Warrant [Member]
Schedule of Assumptions and Estimates Valuation [Line Items]
Fair value of warrants	12.2
Share Price [Member] \| Minimum [Member]
Schedule of Assumptions and Estimates Valuation [Line Items]
Fair value of warrants	12.2
Conversion Rate [Member] \| Minimum [Member]
Schedule of Assumptions and Estimates Valuation [Line Items]
Fair value of warrants	36.4
Floor Rate [Member] \| Minimum [Member]
Schedule of Assumptions and Estimates Valuation [Line Items]
Fair value of warrants	36.4
Exercise Price [Member] \| Warrant [Member]
Schedule of Assumptions and Estimates Valuation [Line Items]
Fair value of warrants	20
Exercise Price [Member] \| Minimum [Member]
Schedule of Assumptions and Estimates Valuation [Line Items]
Fair value of warrants	0.77
Exercise Price [Member] \| Maximum [Member] \| Warrant [Member]
Schedule of Assumptions and Estimates Valuation [Line Items]
Fair value of warrants	36.4
Volatility [Member] \| Warrant [Member]
Schedule of Assumptions and Estimates Valuation [Line Items]
Fair value of warrants	68.63
Volatility [Member] \| Minimum [Member]
Schedule of Assumptions and Estimates Valuation [Line Items]
Fair value of warrants	66.39
Volatility [Member] \| Maximum [Member] \| Warrant [Member]
Schedule of Assumptions and Estimates Valuation [Line Items]
Fair value of warrants	68.27
Risk Free Rate [Member] \| Warrant [Member]
Schedule of Assumptions and Estimates Valuation [Line Items]
Fair value of warrants	3.57
Risk Free Rate [Member] \| Minimum [Member]
Schedule of Assumptions and Estimates Valuation [Line Items]
Fair value of warrants	3.44
Risk Free Rate [Member] \| Maximum [Member] \| Warrant [Member]
Schedule of Assumptions and Estimates Valuation [Line Items]
Fair value of warrants	3.58
Yield [Member] \| Minimum [Member]
Schedule of Assumptions and Estimates Valuation [Line Items]
Fair value of warrants	75.09
Expected Term [Member] \| Warrant [Member]
Schedule of Assumptions and Estimates Valuation [Line Items]
Fair value of warrants	3.77
Expected Term [Member] \| Maximum [Member] \| Warrant [Member]
Schedule of Assumptions and Estimates Valuation [Line Items]
Fair value of warrants	3.95
Dividend Rate [Member] \| Warrant [Member]
Schedule of Assumptions and Estimates Valuation [Line Items]
Fair value of warrants	0

Investments, at Fair Value - Schedule of Refinancing Transaction (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2025

Dec. 31, 2024

Dec. 31, 2023

Schedule of Refinancing Transaction [Line Items]

Balance as of beginning

$ 34,808

$ 110,188

2024 Refinancing

3,425

Proceeds from the sale of Transferred Warrants

(300)

Cash received from Tranche A Note repayment

(64,200)

Exercised warrants

^[1]

(6,123)

Amounts receivable from the royalty agreement

(1,640)

^[2]

(398)

Principal payments

(9,875)

Proceeds from the sale of Subsequent Penny Warrants

(28,500)

Interest payments

(1,845)

Change in fair value

1,637

(7,784)

$ 44,647

Balance as of ending

37,595

34,808

110,188

Tranche A [Member]

Schedule of Refinancing Transaction [Line Items]

Balance as of beginning

16,486

110,188

2024 Refinancing

(21,575)

Proceeds from the sale of Transferred Warrants

(300)

Cash received from Tranche A Note repayment

(64,200)

Exercised warrants

^[1]

(6,123)

Amounts receivable from the royalty agreement

^[2]

Proceeds from the sale of Subsequent Penny Warrants

(28,500)

Change in fair value

(1,504)

35,077

Balance as of ending

23,063

16,486

110,188

Tranche B [Member]

Schedule of Refinancing Transaction [Line Items]

Balance as of beginning

18,322

2024 Refinancing

25,000

Proceeds from the sale of Transferred Warrants

Cash received from Tranche A Note repayment

Exercised warrants

^[1]

Amounts receivable from the royalty agreement

(1,640)

^[2]

(398)

Principal payments

(9,875)

Proceeds from the sale of Subsequent Penny Warrants

Interest payments

(1,845)

Change in fair value

(6,280)

9,570

Balance as of ending

$ 14,532

$ 18,322

[1]	On October 30, 2024 the Company exercised 128,572 Closing Penny Warrants, and 57,143 Subsequent Penny Warrants into 185,715 shares of common stock of Scilex and as a result, these shares are not part of the Tranche A Note. As of December 31, 2025, the Company no longer holds any shares of Scilex common stock.
[2]	As of December 31, 2025, out of this amount $449 is included under prepaid expenses and other current assets.

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2025
Auditor [Table]
Auditor Name	Kesselman & Kesselman C.P.A.s
Auditor Firm ID	1309
Auditor Location	Tel Aviv, Israel
Auditor Opinion [Text Block]	*Opinion on the Financial Statements* We have audited the accompanying consolidated balance sheets of Oramed Pharmaceuticals Inc. and its subsidiaries (the “Company”) as of December 31, 2025 and 2024, and the related consolidated statements of comprehensive income (loss), changes in equity and cash flows for the years then ended, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Equity Method Investee (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Mar. 04, 2025	Feb. 12, 2025	Dec. 31, 2025	Dec. 31, 2024
Equity Method Investee [Line Items]
Loan amount (in Dollars)			$ 7,000
Exercise price per share (in Dollars per share)			$ 4.13	$ 4.13
Expiration term			30 days
Pre funded warrants exercise price per share (in Dollars per share)	$ 0.001		$ 0.35
Pre-Funded Warrants [Member]
Equity Method Investee [Line Items]
Common stock warrant	3,811,617
Royalty Vest Shares [Member]
Equity Method Investee [Line Items]
Number of royalty vest sold			2,600,000
Royalty Vest Warrants [Member]
Equity Method Investee [Line Items]
Number of royalty vest sold			12,502
RoyaltyVest [Member]
Equity Method Investee [Line Items]
Transferred of issued and outstanding capital stock		50.00%
Equity interest, percentage			50.00%
Loan amount (in Dollars)	$ 7,000
Received principal amount (in Dollars)			$ 6,251
ZTlido License Agreement [Member]
Equity Method Investee [Line Items]
Acquired rights, percentage			1.80%
Net profits, percentage			50.00%
Consideration rights amount (in Dollars)			$ 200
Net revenue, percentage			50.00%
Ex-US Product Rights to Gloperba [Member]
Equity Method Investee [Line Items]
Net revenue, percentage			50.00%
BioXcel [Member]
Equity Method Investee [Line Items]
Consideration rights amount (in Dollars)	$ 14,000
Additional shares to warrants purchase	188,383
Number of acquired shares of common stock	4,000,000
Exercise price per share (in Dollars per share)	$ 4.2
Expiration term	5 years
Number of royalty vest sold			4,000,000
Royalty vest continues to hold warrants			1,400,000

Short-Term Borrowings (Details) - USD ($) $ in Thousands	Aug. 08, 2023	May 24, 2024	Aug. 11, 2023
Short-Term Borrowings [Line Items]
Short-term borrowings	$ 99,550
Israel Discount Bank Ltd.[Member]
Short-Term Borrowings [Line Items]
Short-term borrowings		$ 99,550
Minimum [Member]
Short-Term Borrowings [Line Items]
Interest ranging			6.66%
Minimum [Member] \| Short-Term Debt [Member]
Short-Term Borrowings [Line Items]
Short term borrowings maturity date	Aug. 11, 2023
Maximum [Member]
Short-Term Borrowings [Line Items]
Interest ranging		7.38%
Maximum [Member] \| Short-Term Debt [Member]
Short-Term Borrowings [Line Items]
Short term borrowings maturity date	May 24, 2024

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2025	Dec. 31, 2024
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.012	$ 0.012
Common stock, shares authorized (in Shares)	60,000,000	60,000,000
Common stock, shares issued (in Shares)	39,275,006	39,919,545
Common stock, shares outstanding (in Shares)	39,275,006	39,919,545

Loan Agreement Measured in Fair Value

12 Months Ended

Dec. 31, 2025

Loan Agreement Measured in Fair Value [Abstract]

LOAN AGREEMENT MEASURED IN FAIR VALUE

NOTE 7 - LOAN AGREEMENT MEASURED IN FAIR VALUE

On March 24, 2025, the Company entered into a loan agreement with Hapisga Project – New Talpiot Ltd. to finance a purchase of a real estate asset in Jerusalem, Israel in the amount of up to $22,650 (“Hapisga”). The Company lent the amount with a one-year maturity, and a lien was registered on the property reflecting a commitment to register a first-ranking mortgage on a property, which is valued at approximately $890,000, providing significant collateral coverage. The loan bears an annual interest rate of 12%.

In addition, in March 2025, the Company entered into an additional loan agreement with Tova Chochma Im Nachala Ltd. (“Tova Chochma”) in the amount of $5,000. The loan bears an annual interest rate of 12%. The original maturity of the loan was set to be 14 days which was further extended, in April 2025, to up to 12 months. Tova Chochma can repay the loan at any time, with interest accruing until the date of actual repayment (but in no event, less than 6 months). This loan is also secured by the registration of the lien for Hapisga.

In April 2025, the Company loaned $26,921 in connection with the loans to Hapisga and to Tova Chochma.

In May 2025, Tova Chochma repaid an amount of $500 to the Company, which will be offset against final repayment of the loan. The deposit amount does not accrue interest and therefore, the Company will be eligible for the entire interest on Tova Chochma’s portion of the loan’s principal.

The Company decided to designate the loan agreement as a whole under the fair-value option in accordance with ASC Topic 825 “Financial Instruments”. The valuation of the loan agreement was calculated in accordance with the weighted average expected cashflows of the loan. The predicted weighted average cash flows of the loan were discounted at a rate of 9.31%-24.43%. The value of the loan as of December 31, 2025 was $27,943. The changes in the fair value of the loan are recorded in the financial income (loss), net.

The table below represents the fair value breakdown as of December 31, 2025:

	Hapisga		Tova Chochma			Total
Loan	$	21,921	$	5,000		$	26,921
Loan repayment	$		$	(500	)	$	(500	)
Fair value measurement		1,263	$	259		$	1,522
Fair value as of December 31, 2025	$	23,184	$	4,759		$	27,943

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Stock-Based Compensation (Details) $ / shares in Units, $ in Thousands																12 Months Ended
	Sep. 09, 2026 shares	Jun. 18, 2026 shares	Dec. 31, 2025 USD ($) $ / shares shares	Jun. 05, 2025 USD ($) $ / shares shares	Jan. 02, 2025 USD ($) $ / shares shares	Jan. 01, 2025 installments shares	Nov. 11, 2024 USD ($) $ / shares shares	Jul. 01, 2024 installments shares	Jun. 21, 2024 USD ($) $ / shares shares	Jun. 20, 2024 USD ($) $ / shares shares	Apr. 17, 2024 USD ($) $ / shares shares	Apr. 01, 2024 installments shares	Jan. 30, 2024 USD ($) $ / shares shares	Jan. 08, 2024 installments	Jan. 04, 2024 USD ($) $ / shares shares	Dec. 31, 2025 USD ($) shares	Dec. 31, 2024 USD ($) shares
Stock-Based Compensation [Line Items]
Number of options exercisable (in Shares) \| shares			1													1
Number of quarterly installments (in installments) \| installments														12
Fair value grant amount \| $			$ 26,921													$ 26,921
Closing market share price (in Dollars per share) \| $ / shares										$ 2.21
Compensation expenses \| $																5,152	$ 4,053
Expenses recognized in respect of stock options granted to employees \| $																$ 89	213
Unrecognized compensation weighted average period																8 months 19 days
Research and Development Expenses [Member]
Stock-Based Compensation [Line Items]
Compensation expenses \| $																$ 1,893	1,998
General and Administrative Expense [Member]
Stock-Based Compensation [Line Items]
Compensation expenses \| $																$ 3,259	$ 2,055
2019 Plan [Member]
Stock-Based Compensation [Line Items]
Reserved a pool shares (in Shares) \| shares			7,500,000													7,500,000
Maximum term of the options																10 years
RSUs [Member]
Stock-Based Compensation [Line Items]
Options granted (in Shares) \| shares			588,514				135,000								941,500
Fair value grant amount \| $			$ 1,677				$ 321						$ 11		$ 2,250	$ 1,677
Closing market share price (in Dollars per share) \| $ / shares			$ 2.85				$ 2.38								$ 2.39
RSUs vest installments amount (in Shares) \| shares																1,880,104	925,937
Compensation expenses \| $																$ 5,063	$ 3,787
Unrecognized compensation costs \| $			$ 5,041													5,041
Performance Share Units (PSUs) [Member]
Stock-Based Compensation [Line Items]
Options granted (in Shares) \| shares										34,000					294,000
Fair value grant amount \| $										$ 73					$ 691
Closing market share price (in Dollars per share) \| $ / shares															$ 2.39
Compensation expenses \| $																197
Performance Share Units (PSUs) [Member]
Stock-Based Compensation [Line Items]
Options granted (in Shares) \| shares					328,500
Fair value grant amount \| $					$ 792
Closing market share price (in Dollars per share) \| $ / shares					$ 2.41
Board Modified [Member]
Stock-Based Compensation [Line Items]
Options granted (in Shares) \| shares					294,000
Fair value modification \| $					$ 13
Three Equal Quarterly Installments [Member]
Stock-Based Compensation [Line Items]
Options granted (in Shares) \| shares											29,800				187,610
Number of quarterly installments (in installments) \| installments						3		3				3
Fair value grant amount \| $				$ 323							$ 69				$ 448
Closing market share price (in Dollars per share) \| $ / shares											$ 2.33				$ 2.39
RSUs vest installments amount (in Shares) \| shares						22,500		7,300				37,610
Number of annual installments (in installments) \| installments						3
Number of installment			4	3
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price (in Dollars per share) \| $ / shares				$ 2.15
Three Equal Quarterly Installments [Member] \| RSUs [Member]
Stock-Based Compensation [Line Items]
Options granted (in Shares) \| shares			20,900	150,000
Fair value grant amount \| $			$ 60													60
Closing market share price (in Dollars per share) \| $ / shares			$ 2.85
RSUs vest installments amount (in Shares) \| shares						150,000
Four Equal Quarterly Installments [Member]
Stock-Based Compensation [Line Items]
Number of installment	4
Four Equal Quarterly Installments [Member] \| RSUs [Member]
Stock-Based Compensation [Line Items]
Options granted (in Shares) \| shares									140,040				3,750
Number of quarterly installments (in installments) \| installments												4
Fair value grant amount \| $									$ 305
Closing market share price (in Dollars per share) \| $ / shares									$ 2.18				$ 2.98
Four Equal Quarterly Installments [Member] \| RSUs [Member] \| Forecast [Member]
Stock-Based Compensation [Line Items]
RSUs vest installments amount (in Shares) \| shares	46,680	93,360
Number of installment		1
Equal Quarterly Installments [Member]
Stock-Based Compensation [Line Items]
RSUs vest installments amount (in Shares) \| shares					85,249
Number of installment					3
Equal Quarterly Installments [Member] \| RSUs [Member]
Stock-Based Compensation [Line Items]
Options granted (in Shares) \| shares					1,023,000
Fair value grant amount \| $					$ 2,465
Closing market share price (in Dollars per share) \| $ / shares					$ 2.41
Four Monthly Installments [Member]
Stock-Based Compensation [Line Items]
Options granted (in Shares) \| shares				34,876
Number of installment				4
Four Monthly Installments [Member] \| RSUs [Member]
Stock-Based Compensation [Line Items]
Fair value grant amount \| $				$ 75
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price (in Dollars per share) \| $ / shares				$ 2.15
Three Equal Annual Installments [Member]
Stock-Based Compensation [Line Items]
Fair value grant amount \| $			$ 342													342
Closing market share price (in Dollars per share) \| $ / shares			$ 2.85
Number of installment			3
Three Equal Annual Installments [Member] \| RSUs [Member]
Stock-Based Compensation [Line Items]
Options granted (in Shares) \| shares			120,000
Eleven Equal Quarterly Installments [Member]
Stock-Based Compensation [Line Items]
Options granted (in Shares) \| shares			616,000
Fair value grant amount \| $			$ 1,756													1,756
Closing market share price (in Dollars per share) \| $ / shares			$ 2.85
Number of installment			11
Eleven Equal Quarterly Installments [Member] \| Performance Share Units (PSUs) [Member]
Stock-Based Compensation [Line Items]
Options granted (in Shares) \| shares			166,000
Fair value grant amount \| $			$ 472													$ 472
Closing market share price (in Dollars per share) \| $ / shares			$ 2.85
Non-Employees [Member]
Stock-Based Compensation [Line Items]
Options granted (in Shares) \| shares																47,000	47,000

Income (Loss) Per Share of Common Stock (Details) - shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Income (Loss) Per Share of Common Stock [Abstract]
Antidilutive shares	1,847,946	3,549,490

Investment In Real Estate

12 Months Ended

Dec. 31, 2025

Investment In Real Estate [Abstract]

INVESTMENT IN REAL ESTATE

NOTE 5 – INVESTMENT IN REAL ESTATE

Real Estate – Castel

In January 2025, the Company entered into an agreement to acquire a parcel of land in Mevaseret Zion, Israel for a total purchase price of NIS 5,800 ($1,586). The transaction was structured as installment payments, and as of December 31, 2025, the Company had paid the full purchase price and presented the asset within real estate investment. The Company intends to pursue value-enhancing activities in connection with the land, with the goal of increasing its potential return upon future sale. The total paid amount is included under Investment in real estate.

Stockholders' Equity

12 Months Ended

Dec. 31, 2025

Stockholders’ Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 14 - STOCKHOLDERS’ EQUITY:

The following are the significant capital stock transactions that took place during the years ended December 31, 2025 and 2024:

On March 18, 2024, the Company entered into an at the market offering (the “StockBlock ATM Agreement”) with Rodman & Renshaw LLC and StockBlock Securities LLC, as agent, pursuant to which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $75,000, through a sales agent, subject to certain terms and conditions. Any shares sold will be sold pursuant to the Company’s effective shelf registration statement on Form S-3 including a prospectus dated March 18, 2024 and prospectus supplement dated September 1, 2021. The Company will pay the sales agent a cash commission of 3.0% of the gross proceeds of the sale of any shares sold through the sales agent under the StockBlock ATM Agreement. As of December 31, 2025 no shares had been issued under the StockBlock ATM Agreement.

As of December 31, 2025 and 2024, the Company had outstanding warrants exercisable for 20,000 shares of common stock at an exercise price of $4.13 per share, which become exercisable on February 25, 2020 and expire on April 15, 2029. There was no warrant activity during the years ended December 31, 2025 and 2024.

Buyback program

In June 2024, the Company’s board of directors authorized a stock buyback program pursuant to which the Company may, from time to time, repurchase and retire up to $20,000 in maximum value of its common stock. Share repurchases may be executed through various means, including, without limitation, open market transactions, privately negotiated transactions or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The stock buyback program does not obligate the Company to purchase any shares and expires in June 2025. The authorization for the stock buyback program may be terminated, increased or decreased by the Company’s board of directors in its discretion at any time.

On May 21, 2025, the Company’s board of directors authorized a one-year extension of the Company’s current stock buyback program, which was set to expire in June 2026, pursuant to which the Company may, from time to time, purchase up to $20,000 in maximum value of its common stock.

During 2025 and 2024, the Company repurchased and retired shares of its common stock under this program. During 2025 the Company repurchased 899,609 shares for $2,155, including $6 of excise tax, at an average price of $2.39 per share and during 2024, the Company repurchased 1,036,976 shares for $2,494, including $10 of excise tax, at an average price of $2.4 per share. All repurchases were funded with cash on hand.

As of December 31, 2025, the Company has repurchased 1,936,585 shares of its common stock under this program in the total amount of $4,649.

On October 20, 2025, the Company entered into a share repurchase agreement with HTIT, pursuant to which the Company repurchased and retired 1,155,367 shares of its common stock at a purchase price of $2.23 per share, for an aggregate price of $2,584, including $8 of excise tax. The repurchased shares were cancelled and retired upon closing.

Dividends to Shareholders

On December 31, 2025, the Company’s Board of Directors declared a special cash dividend of $0.25 per share of common stock, payable to holders of record as of the close of business on January 16, 2026. The dividend was paid on January 26, 2026. In accordance with the terms of the Company’s outstanding warrant agreements, holders of 20,000 warrants as of the record date were also entitled to receive a cash payment of $0.25 per underlying warrant share. Holders of RSUs granted prior to the record date, including unvested RSUs, were entitled to receive a dividend equivalent of $0.25 per RSU unit, payable upon vesting of the underlying awards, as described below. The aggregate dividend and dividend equivalent amount, including amounts attributable to outstanding warrants and unvested RSUs, totaled $10,870. The dividend was unpaid as of December 31, 2025 and is recorded in dividends payable in the consolidated balance sheets.

Dividend equivalents declared on unvested RSUs are subject to the same vesting conditions as the underlying awards and are forfeited if the awards do not vest. Such dividend equivalents are deferred and will be paid to RSU holders upon vesting of the underlying award. In accordance with ASC 718, forfeitable dividend equivalents on equity-classified awards are recognized as a charge to retained earnings at the date of declaration, with a corresponding liability recorded in dividends payable.

Waiver of loan granted to subsidiary– Oravax

As of December 31, 2025, Oravax ceased its operations. As a result, the Company waved the loan owed by Oravax to the Company (“waver of the loan”). In connection with the waiver of the loan owed by Oravax to the Company, which effectively constituted a benefit to the non-controlling interest, the Company recognized the impact as an adjustment to non-controlling interest balance, with a corresponding adjustment to additional paid-in capital.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Investment in Associate at Fair Value (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Jun. 23, 2025	Apr. 24, 2025	Dec. 31, 2025	Oct. 30, 2025	Dec. 31, 2024
Investment In Associated at Fair Value [Line Items]
Non-refundable fee			$ 3,000
Purchase of warrants shares (in Shares)			20,000	100,000	20,000
Warrant exercise price per shares (in Dollars per share)			$ 4.13		$ 4.13
Investment fair value			$ 37,595
Percentage of voting interest		17.00%	17.00%
Fair value of warrants	$ 2,727
ALPHA Tau Warrants [Member]
Investment In Associated at Fair Value [Line Items]
Purchase of warrants shares (in Shares)			3,237,000
Fair value of warrants			$ 6,242
Share Purchase Agreement [Member]
Investment In Associated at Fair Value [Line Items]
Purchased ordinary shares (in Shares)		14,110,121	359,214
Percentage of ordinary shares		16.65%
Price per share (in Dollars per share)		$ 2.612
Aggregate purchase price		$ 36,900
Alpha Tau [Member]
Investment In Associated at Fair Value [Line Items]
Purchase of warrants shares (in Shares)			3,237,000
Investment fair value		$ 36,885	$ 71,623
Unrealized gain on its investment			$ 36,997
Price per ordinary share (in Dollars per share)		$ 2.612	$ 4.95
Fair value of warrants			$ 2,727
Alpha Tau [Member] \| Share Purchase Agreement [Member]
Investment In Associated at Fair Value [Line Items]
Purchased ordinary shares (in Shares)			1,256
Minimum [Member] \| ALPHA Tau Warrants [Member]
Investment In Associated at Fair Value [Line Items]
Warrant exercise price per shares (in Dollars per share)			$ 3.474
Maximum [Member] \| ALPHA Tau Warrants [Member]
Investment In Associated at Fair Value [Line Items]
Warrant exercise price per shares (in Dollars per share)			$ 3.9

Loan Agreement Measured in Fair Value (Tables)

12 Months Ended

Dec. 31, 2025

Loan Agreement Measured in Fair Value [Abstract]

Schedule of Fair Value Breakdown

The table below represents the fair value breakdown as of December 31, 2025:

	Hapisga		Tova Chochma			Total
Loan	$	21,921	$	5,000		$	26,921
Loan repayment	$		$	(500	)	$	(500	)
Fair value measurement		1,263	$	259		$	1,522
Fair value as of December 31, 2025	$	23,184	$	4,759		$	27,943

Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2025

Significant Accounting Policies [Abstract]

Schedule of Fair Value Measurements on a Recurring Basis

The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:

	December 31, 2025
	Level 1		Level 2		Level 3		Fair Value
Assets:
Marketable Securities
DNA		540		-		-		540
Entera		227		-		-		227
Nano		8,371		-		-		8,371
Pelthos		4,650		-		-		4,650
Investment in Alpha Tau’s shares (see note 8)		71,623		-		-		71,623
Loan to an equity method investee (see note 6)		-		-		553		553
Warrants Note B (see note 4)		-		-		850		850
Tranche A Note (see note 4)		-		-		23,063		23,063
Tranche B Note (see note 4)		-		-		11,473		11,473
Royalty Purchase Agreement (see note 4)		-		-		2,209		2,209
Profit Sharing Loan Agreement (see note 4 (e))		-		-		1,890		1,890
Loan agreement measured in fair value (see note 7)		-		-		27,943		27,943
Investment in Alpha Tau’s warrants (see note 8)		-		-		6,242		6,242
Convertible note (see note 9)		-		-		4,636		4,636
	$	85,411	$	-	$	78,859	$	164,270

	December 31, 2024
	Level 1		Level 2		Level 3		Fair Value
Assets:
Marketable Securities
DNA		424		-		-		424
Entera		248		-		-		248
Scilex		2,769		-		-		2,769
Subsequent Penny Warrants (see note 4)		-		2,772		-		2,772
Warrants Note B (see note 4)		-		-		548		548
Tranche A Note (see note 4)		-		-		13,714		13,714
Tranche B Note (see note 4)		-		-		15,798		15,798
Royalty Purchase Agreement (see note 4)		-		-		1,976		1,976
Profit Sharing Loan Agreement (see note 4)		-		-		1,367		1,367
	$	3,441	$	2,772	$	33,403	$	39,616

- Definition

Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.

+ References + Details

Stock-Based Compensation - Schedule of Stock Options Granted to Employees and Directors (Details) - Stock Options [Member]	12 Months Ended
	Dec. 31, 2025 $ / shares shares	Dec. 31, 2024 $ / shares shares
Schedule of Stock Options Granted to Employees and Directors [Line Items]
Number of options, Options outstanding at beginning \| shares	1,661,008	1,909,676
Weighted average exercise price, Options outstanding at beginning \| $ / shares	$ 7.21	$ 8.03
Changes during the year:
Number of options, Granted \| shares
Weighted average exercise price, Granted \| $ / shares
Number of options, Forfeited \| shares	(625)	(49,125)
Weighted average exercise price, Forfeited \| $ / shares	$ 13.89	$ 13.92
Number of options, Expired \| shares		(199,543)
Weighted average exercise price, Expired \| $ / shares		$ 13.4
Number of options, Exercised \| shares
Weighted average exercise price, Exercised \| $ / shares
Number of options, Options outstanding at ending \| shares	1,660,383	1,661,008
Weighted average exercise price, Options outstanding at ending \| $ / shares	$ 7.21	$ 7.21
Number of options, Options exercisable at end of year \| shares	1,501,633	1,442,258
Weighted average exercise price, Options exercisable at end of year \| $ / shares	$ 7.18	$ 6.91

Loan Agreement Measured in Fair Value - Schedule of Fair Value Breakdown (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($)
Schedule of Fair Value Breakdown [Line Items]
Loan	$ 26,921
Loan repayment	(500)
Fair value measurement	1,522
Fair value as of December 31, 2025	27,943
Hapisga [Member]
Schedule of Fair Value Breakdown [Line Items]
Loan	21,921
Loan repayment
Fair value measurement	1,263
Fair value as of December 31, 2025	23,184
Tova Chochma [Member]
Schedule of Fair Value Breakdown [Line Items]
Loan	5,000
Loan repayment	(500)
Fair value measurement	259
Fair value as of December 31, 2025	$ 4,759

Income (Loss) Per Share of Common Stock - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Basic income (loss) per common stock (numerator):
Net income (loss) applicable to common stock	$ 64,050	$ (19,060)
Adjustment for dividends attributable to unvested RSUs	(808)
Net income (loss) applicable to common stock – basic	$ 63,242	$ (19,060)
common stock (denominator):
Weighted average number of common stock – basic (in Shares)	41,402,997	40,850,446
Basic income (loss) per common stock (in Dollars per share)	$ 1.53	$ (0.48)
Diluted income (loss) per common stock (numerator):
Net income (loss) applicable to common stock – basic	$ 63,242	$ (19,060)
Adjustment for dividends attributable to unvested RSUs	359
Net income (loss) applicable to common stock – diluted	$ 63,601	$ (19,060)
common stock (denominator):
Weighted average number of common stock – basic (in Shares)	41,402,997	40,850,446
Diluted effect of RSUs (in Shares)	1,015,647
Weighted average number of common stock – diluted (in Shares)	42,418,644	40,850,446
Diluted income (loss) per common stock (in Dollars per share)	$ 1.5	$ (0.48)

Marketable Securities

12 Months Ended

Dec. 31, 2025

Marketable Securities [Abstract]

MARKETABLE SECURITIES

NOTE 3 - MARKETABLE SECURITIES:

Composition:

The Company’s marketable securities include investments in equity securities of DNA, Entera, Scilex, Nano and Pelthos.

	December 31,
	2025		2024
Short-term:
DNA (see b below)	$	540	$	424
Entera (see c below)		227		248
Scilex (see d below)		-		2,769
Pelthos (see f below)		4,650		-
	$	5,417		3,441

	December 31,
	2025		2024
Long-term:
Nano (see e below)		8,371		-
	$	8,371		-

DNA

DNA’s ordinary shares are traded on the Tel Aviv Stock Exchange. The fair value of those securities is measured at the quoted prices of the securities on the measurement date.

During the years ended December 31, 2025 and 2024, the Company did not sell any of DNA’s ordinary shares. The Company recognized an unrealized gain on its investment in DNA of $116 in the consolidated statement of comprehensive income (loss) for the year ended December 31, 2025. As of December 31, 2025, the Company owns approximately 0.20% of DNA’s outstanding ordinary shares.

Entera

Entera ordinary shares have been traded on the Nasdaq Capital Market since June 28, 2018. The Company measures the investment at fair value from such date, since it has a readily determinable fair value. The fair value of those securities is measured at the quoted prices of the securities on the measurement date.

During the years ended December 31, 2025 and 2024, the Company did not sell any of Entera’s ordinary shares. The Company recognized an unrealized gain on its investment in Entera of $(21) in the consolidated statement of comprehensive income (loss) for the year ended December 31, 2025. As of December 31, 2025, the Company owns approximately 0.26% of Entera’s outstanding ordinary shares.

Scilex

Scilex common stock are traded on the Nasdaq Capital Market. The fair value of those securities is measured at the quoted prices of the securities on the measurement date.

Through December 31, 2025, the Company sold all shares of Scilex common stock for total gross proceeds of $2,865. Following the sale, the Company no longer holds any shares of Scilex common stock.

Nano

On November 11, 2025, the Company purchased ordinary shares of Nano Dimension Ltd (“Nano”), through December 31, 2025, the Company purchased 5,436,791 ordinary shares for an aggregate purchase price of $8,501. The aggregate purchase price excludes transaction fees equal to 1% of the number of shares purchased in each transaction, amounting to $54, which were expensed as incurred. The fair value of those securities is measured at the quoted prices of the securities on the measurement date.

The Company recognized an unrealized gain on its investment in Nano of $(130) in the consolidated statement of comprehensive income (loss) for the year ended December 31, 2025. As of December 31, 2025, the Company owns approximately 2.58% of Nano’s outstanding ordinary shares. For more information, see note 21.

Pelthos

On July 1, 2025, the Company entered into a securities purchase agreement with Pelthos Therapeutics Inc. (“Pelthos”), pursuant to which the Company invested $1,500 and acquired 150,000 shares of Pelthos common stock. The Company recognized an unrealized gain on its investment in Pelthos of $3,150 in the consolidated statement of comprehensive income (loss) for the year ended December 31, 2025.

Pelthos common stock are traded on the Nasdaq Capital Market. The fair value of those securities is measured at the quoted prices of the securities on the measurement date. As of December 31, 2025, the Company owns approximately 4.9% of Pelthos’s outstanding common stock. For more information, see note 21.

Consolidated Statements of Changes in Equity (Parentheticals)	12 Months Ended
	Dec. 31, 2025 $ / shares
Statement of Stockholders' Equity [Abstract]
Dividend on common stock, per share (in Dollars per share)	$ 0.25

Related Party Transactions - Schedule of Related Parties (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Related Party Transaction [Line Items]
Total payable to related parties	$ 652	$ 329
Total expenses to related parties	1,712	1,374
Shnida [Member]
Related Party Transaction [Line Items]
Total payable to related parties	380	175
Total expenses to related parties	768	514
Miriam Kidron [Member]
Related Party Transaction [Line Items]
Total payable to related parties	272	154
KNRY [Member]
Related Party Transaction [Line Items]
Total expenses to related parties	562	563
Miriam Kidron Chief Scientific Officer [Member]
Related Party Transaction [Line Items]
Total expenses to related parties	150
Nadav Kidron (President and Chief Executive Officer) [Member]
Related Party Transaction [Line Items]
Total expenses to related parties	$ 232	$ 297

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Common Stock	Additional paid-in capital	Accumulated deficit	Total stockholders’ equity	Non- controlling interests	Total
BALANCE at Dec. 31, 2023	$ 485	$ 320,892	$ (157,556)	$ 163,821	$ (928)	$ 162,893
BALANCE (in Shares) at Dec. 31, 2023	40,339,000
STOCK-BASED COMPENSATION	$ 7	3,991		3,998		3,998
STOCK-BASED COMPENSATION (in Shares)	618,000
STOCK-BASED COMPENSATION OF SUBSIDIARY					53	53
REPURCHASE AND RETIREMENT OF COMMON STOCK	$ (12)	(2,482)		(2,494)		(2,494)
REPURCHASE AND RETIREMENT OF COMMON STOCK (in Shares)	(1,037,000)
NET INCOME (LOSS)			(19,060)	(19,060)	(43)	(19,103)
BALANCE at Dec. 31, 2024	$ 480	322,401	(176,616)	146,265	(918)	145,347
BALANCE (in Shares) at Dec. 31, 2024	39,920,000
STOCK-BASED COMPENSATION	$ 17	5,975		5,992		5,992
STOCK-BASED COMPENSATION (in Shares)	1,410,000
REPURCHASE AND RETIREMENT OF COMMON STOCK	$ (25)	(4,716)		(4,741)		(4,741)
REPURCHASE AND RETIREMENT OF COMMON STOCK (in Shares)	(2,055,000)
DIVIDEND ON COMMON STOCK ($0.25 PER SHARE)			(10,870)	(10,870)		(10,870)
WAIVER OF LOAN GRANTED TO SUBSIDIARY		(952)		(952)	952
NET INCOME (LOSS)			64,050	64,050	(34)	64,016
BALANCE at Dec. 31, 2025	$ 472	$ 322,708	$ (123,436)	$ 199,744		$ 199,744
BALANCE (in Shares) at Dec. 31, 2025	39,275,000

Commitments - Schedule of Right-of-Use Assets Over the Remaining Lease (Details) - USD ($)
$ in Thousands

Dec. 31, 2025

Dec. 31, 2024

Schedule of Right-of-Use Assets Over the Remaining Lease [Abstract]

$ 332

192

163

157

104

Total undiscounted lease payments

948

Less: Interest

^[1]

(123)

Present value of lease liabilities

$ 825

$ 372

[1]	Future lease payments were discounted by 3%-7% interest rate.

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
CURRENT ASSETS:
Cash and cash equivalents	$ 45,947	$ 54,420
Short-term deposits (note 2)	10,979	55,281
Marketable securities (note 3)	5,417	3,441
Investments at fair value (note 4,7)	63,551	28,788
Convertible note (note 9)	4,636
Prepaid expenses and other current assets	2,741	1,291
Total current assets	133,271	143,221
LONG-TERM ASSETS:
Long-term deposits	2	2
Marketable securities (note 3)	8,371
Investments at fair value (note 4,7)	10,119	7,387
Investment in associate at fair value (note 8)	71,623
Loan to an equity method investee (note 6)	553
Investment in real estate (note 5)	1,921
Other non-marketable equity securities (note 10)	3,624	3,524
Amounts funded in respect of employee rights upon retirement	44	32
Property and equipment, net	586	698
Operating lease right of use assets	750	414
Total long-term assets	97,593	12,057
Total assets	230,864	155,278
CURRENT LIABILITIES:
Accounts payable and accrued expenses (note 11)	6,201	5,140
Payable to related parties (note 20)	652	329
Deferred income (note 8)	1,353
Dividend Payable	10,595
Operating lease liabilities	285	216
Total current liabilities	19,086	5,685
LONG-TERM LIABILITIES:
Long-term deferred revenues (note 13)	2,000	4,000
Long-term deferred income (note 8)	1,269
Employee rights upon retirement	39	30
Operating lease liabilities	540	156
Dividend Payable	275
Other liabilities		60
Deferred tax liabilities (note 18)	7,911
Total long-term liabilities	12,034	4,246
COMMITMENTS (note 13)
EQUITY ATTRIBUTABLE TO COMPANY’S STOCKHOLDERS:
Common stock, $ 0.012 par value (60,000,000 authorized shares as of December 31, 2025 and December 31, 2024; 39,275,006 and 39,919,545 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively)	472	480
Additional paid-in capital	322,708	322,401
Accumulated deficit	(123,436)	(176,616)
Total stockholders’ equity	199,744	146,265
Non-controlling interests		(918)
Total equity	199,744	145,347
Total liabilities and equity	$ 230,864	$ 155,278

Related Party Transactions

12 Months Ended

Dec. 31, 2025

RELATED PARTY TRANSACTIONS

NOTE 20 - RELATED PARTY TRANSACTIONS:

Chief Scientific Officer

On July 1, 2008, the Subsidiary entered into a consulting agreement with KNRY Ltd. (“KNRY”), an Israeli company owned by the Company’s Chief Scientific Officer, whereby the Chief Scientific Officer, through KNRY, provides services to the Company (the “Consulting Agreement”). The Consulting Agreement is terminable by either party upon 140 days prior written notice. The Consulting Agreement, as amended, provides that KNRY will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreement.

Effective as of July 1, 2024, the monthly consulting fee of the Chief Scientific Officer is NIS 134,550 ($40).

Effective as of April 1, 2025, the Company entered into a consulting agreement with KNRY, whereby the Chief Scientific Officer, through KNRY, provides services as Chief Scientific Officer of the Company. The agreement is terminable by either party upon 140 days prior written notice. The agreement provides that KNRY will be reimbursed for reasonable expenses incurred in connection with performance of the agreement. The Chief Scientific Officer receives a monthly consulting fee of NIS 67,275 ($20). Pursuant to the agreement, KNRY and the Chief Scientific Officer each agree that during the term of the agreement and for a 12-month period thereafter, none of them will compete with the Company nor solicit employees of the Company.

Effective as of January 1, 2026, monthly consulting fee of the Chief Scientific Officer is NIS 71,648 ($22).

In addition, the Company, through the Subsidiary, has entered into an employment agreement with the Chief Scientific Officer, effective as of April 1, 2025, pursuant to which the Chief Scientific Officer receives a gross monthly salary of NIS 51,750 ($16) in consideration for her services as Chief Scientific Officer of the Subsidiary. In addition, the Chief Scientific Officer is provided with a phone and a company car pursuant to the terms of her agreement.

Effective as of January 1, 2026, the gross monthly salary of the Chief Scientific Officer is NIS 55,114 ($17).

President and Chief Executive Officer

Effective as of July 1, 2024, the Company entered into a consulting agreement with Shnida Ltd. (“Shnida”), whereby the Company’s President and Chief Executive Officer, through Shnida, provides services as President and Chief Executive Officer of the Company. The agreement is terminable by either party upon 140 days prior written notice. The agreement provides that Shnida will be reimbursed for reasonable expenses incurred in connection with performance of the agreement. Effective as of January 1, 2024, the President and Chief Executive Officer receives a monthly consulting fee of NIS 111,349 ($34). Pursuant to the agreement, Shnida and the President and Chief Executive Officer each agree that during the term of the agreement and for a 12-month period thereafter, none of them will compete with the Company nor solicit employees of the Company.

Effective as of January 1, 2026, the monthly consulting fee of the Chief Executive Officer is NIS 118,587 ($37).

In addition, the Company, through the Subsidiary, has entered into an employment agreement with the President and Chief Executive Officer, effective as of July 1, 2024, pursuant to which, effective as of January 1, 2024, the President and Chief Executive Officer receives gross monthly salary of NIS 59,330 ($18) in consideration for his services as President and Chief Executive Officer of the Subsidiary. In addition, the President and Chief Executive Officer are provided with a phone and a company car pursuant to the terms of his agreement.

Effective as of January 1, 2026, the gross monthly salary of the Chief Executive Officer is NIS 63,186 ($20).

Balances with related parties:

	December 31,
	2025		2024
Accounts payable and accrued expenses - Shnida	$	380	$	175
Accounts payable and accrued expenses - Miriam Kidron		272		154
Total payable to related parties	$	652	$	329

Expenses to related parties:

	Year ended December 31,
	2025		2024
KNRY	$	562	$	563
Miriam Kidron (Chief Scientific Officer)		150		-
Shnida		768		514
Nadav Kidron (President and Chief Executive Officer)		232		297
Total expenses to related parties	$	1,712	$	1,374

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

Taxes on Income

12 Months Ended

Dec. 31, 2025

Taxes on Income [Abstract]

TAXES ON INCOME

NOTE 18 - TAXES ON INCOME:

Taxes on income included in the consolidated statements of comprehensive income (loss) represent current taxes due to taxable income of the Company.

Corporate taxation in the U.S.

The applicable corporate tax rate for the Company is 21%.

As of December 31, 2025, the Company has utilized all of its outstanding net operating loss (“NOL”). Oravax had an accumulated tax loss carryforward of approximately $3,395 (as of December 31, 2024, $3,386). Under U.S. tax laws, subject to certain limitations, carryforward tax losses originating in tax years beginning after January 1, 2018, have no expiration date, but they are limited to 80% of the company’s taxable income in any given tax year. Carryforward tax losses originating in tax years beginning prior to January 1, 2018, expire 20 years after the year in which incurred.

Corporate taxation in Israel

The Subsidiary is taxed in accordance with Israeli tax laws. The corporate tax rate applicable to 2025 and 2024 is 23%.

As of December 31, 2025, the Subsidiary and Oravax Medical Ltd. had an accumulated tax loss carryforward of approximately $115,623 (as of December 31, 2024, approximately $113,419). Under the Israeli tax laws, carryforward tax losses have no expiration date.

Cash paid for income taxes

Cash paid for U.S. federal income taxes was $3,318 and $0 for the years ended December 31, 2025 and 2024, respectively.

Deferred income taxes

	December 31,
	2025			2024
In respect of:
Net operating loss carryforward	$	27,306		$	26,797
Research and development expenses		1,005			1,220
Revaluation of investments		(7,973	)		5,608
Other temporary differences		134			2,495
Less - valuation allowance		(28,383	)		(36,120	)
Net deferred tax liability	$	(7,911	)	$	-

Deferred taxes are determined based on temporary differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.

Income (Loss) before taxes on income and income taxes included in the consolidated statements of comprehensive income (loss)

	Year ended December 31,
	2025			2024
Income (loss) before taxes on income:
U.S.	$	46,424		$	(8,853	)
Outside U.S.		28,900			(7,067	)
	$	75,324		$	(15,920	)
Taxes on income (tax benefit):
Current:
U.S.		3,573			3,183
Outside U.S.		-			-
	$	3,573		$	3,183

Deferred Taxes:
U.S.	$	(184	)	$	-
Outside U.S.		8,095			-
	$	7,911		$	-
Prior Year Taxes:
U.S.		(176	)		-
Outside U.S.		-			-
	$	(176	)	$	-

Total Taxes:
U.S.	$	3,213		$	3,183
Outside U.S.		8,095			-
	$	11,308		$	3,183

Reconciliation of the statutory tax benefit to effective tax expense

Following is a reconciliation of the theoretical tax expense, assuming all income is taxed at the regular tax rates applicable to companies in the United States, and the actual tax expense. The amounts for 2024 are presented prior to the adoption of ASU 2023-09, while the amounts for 2025 are presented after its adoption.

	2024
Income (loss) before taxes expenses	$	(15,920	)

Statutory tax (benefit) expense – 21%		(3,343	)
Increase (decrease) in income taxes resulting from:
Change in valuation allowance		7,647
Disallowable deductions		(878	)
Influence of different tax rate applicable to the Subsidiary and Oravax Medical Ltd.		(219	)
Prior year adjustments		(13	)
Uncertain tax position		(11	)
Taxes on income for the reported year	$	3,183

Year ended December 31, 2025

	Amount			Percent
U.S. federal statutory tax rate	$	15,818			21
Foreign tax effects
Israel
Share-based payment awards		2,573			3.4
Changes In Valuation allowance		(1,137	)		(1.5	)
Statutory tax rate difference between Israel and United States		579			0.8
Other		13			0.0
Effect of cross-border tax laws		114			0.2
Change in the valuation allowance		(6,600	)		(8.8	)
Nontaxable or nondeductible items		122			0.2
Other		(174	)		(0.2	)
Effective Tax Rate	$	11,308			15.0

Uncertainty in Income Taxes

ASC 740, “Income Taxes” requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company. The Company recognizes interest and penalties related to its tax contingencies as income tax expense.

The following table summarizes the activity of the Company unrecognized tax benefits:

	Year ended December 31,
	2025		2024
Balance at Beginning of Year	$	-	$	11
Decrease in uncertain tax positions for the current year		-		(11	)
Balance at End of Year	$	-	$	-

The Company does not expect unrecognized tax expenses to change significantly over the next 12 months.

The Company is subject to U.S. Federal income tax examinations for the tax years of 2021 through 2025.

The Subsidiary is subject to Israeli income tax examinations for the tax years of 2019 through 2025.

Valuation Allowance Rollforward

	Year ended
	Balance at beginning of year		Additions (deductions)			Balance at end of year
Allowance in respect of carryforward tax losses:
Year ended December 31, 2025	$	36,120	$	(7,737	)	$	28,383
Year ended December 31, 2024	$	28,473	$	7,647		$	36,120

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Other Non-Marketable Equity Securities

12 Months Ended

Dec. 31, 2025

Other Non-Marketable Equity Securities [Abstract]

OTHER NON-MARKETABLE EQUITY SECURITIES

NOTE 10 - OTHER NON-MARKETABLE EQUITY SECURITIES:

On August 26, 2022, the Company entered into a stock purchase agreement with Diasome Pharmaceuticals, Inc. (“Diasome”), a privately-held company, pursuant to which the Company purchased shares of Series B preferred stock of Diasome for an aggregate purchase price of approximately $2,700. Following the purchase, the Company holds less than 5% of the issued and outstanding stock of Diasome. The stock purchase agreement provides the Company with the option to purchase additional preferred shares of stock on a pro rata basis at similar terms to the terms and conditions of the current round contingent upon Diasome achieving certain milestones.

The Company’s non-marketable equity securities are an investment in a company without a readily determinable fair value. The Company accounts for this investment under the measurement alternative in ASC 321, whereby the equity investment is recorded at cost, less impairment. The carrying amount is subsequently remeasured to its fair value in accordance with the provisions of ASC 820 when observable price changes occur as of the date the transaction occurred, or it is impaired. Any adjustments to the carrying amount are recorded in the consolidated statements of comprehensive income (loss).

During the years ended December 31, 2025 and 2024, there was no change in the value of the Diasome investment.

Segment Reporting

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

SEGMENT REPORTING

NOTE 19 - SEGMENT REPORTING:

The Company’s Chief Executive Officer, serving as the Chief Operating Decision Maker (CODM), evaluates operational performance and makes resource allocation decisions based on net income (loss), which is reported in the consolidated statements of comprehensive income. The Company has determined that it operates in a single reportable segment, focused on research and development activities related to its proprietary products and technologies.

The CODM monitors budgeted versus actual net income, using this measure to assess segment performance and guide financial planning, which is consistent with the financial statements. In addition to its research and development activities, the Company holds financial investments, including a material investment in Scilex, Hapisga and Alpha Tau, see note 4, note 7 and note 8. The CODM monitors these investments separately from operational performance. Income and expenses related to financial instruments are reported as financial income in the consolidated statements of comprehensive income, reflecting their distinct nature from core business operations.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Income Statement [Abstract]
REVENUES	$ 2,000
COST OF REVENUE	(1,987)
GROSS PROFIT	13
RESEARCH AND DEVELOPMENT EXPENSES	(6,381)	(6,324)
GENERAL AND ADMINISTRATIVE EXPENSES	(8,720)	(6,457)
OPERATING LOSS	(15,088)	(12,781)
OTHER INCOME, NET	958
INTEREST EXPENSES (note 12)		(853)
FINANCIAL INCOME (LOSS), NET (note 17)	89,454	(2,286)
INCOME (LOSS) BEFORE TAX EXPENSES	75,324	(15,920)
TAX EXPENSES	(11,308)	(3,183)
NET INCOME (LOSS)	64,016	(19,103)
NET INCOME (LOSS) ATTRIBUTABLE TO:
NON-CONTROLLING INTERESTS	(34)	(43)
COMPANY’S STOCKHOLDERS	$ 64,050	$ (19,060)
BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share)	$ 1.53	$ (0.48)
DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share)	$ 1.5	$ (0.48)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares)	41,402,997	40,850,446
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares)	42,418,644	40,850,446

Stock-Based Compensation - Schedule of Concerning the Options Granted to Non Employees Outstanding (Details) - Non-Employees [Member] - 3.74-5.08 [Member]	12 Months Ended
	Dec. 31, 2025 $ / shares shares
Schedule of Concerning the Options Granted to Non Employees Outstanding [Line Items]
Number outstanding \| shares	47,000
Weighted Average Remaining Contractual Life Years	3 years 11 months 23 days
Weighted average exercise price \| $ / shares	$ 4.31

Taxes on Income - Schedule of Income (Loss) Before Taxes on Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Income (loss) before taxes on income:
Income (loss) before taxes on income	$ 75,324	$ (15,920)
Taxes on income (tax benefit)	3,573	3,183
Deferred Taxes:	7,911
Prior Year Taxes	(176)
Total Taxes	11,308	3,183
U.S. [Member]
Income (loss) before taxes on income:
Income (loss) before taxes on income	46,424	(8,853)
Taxes on income (tax benefit)	3,573	3,183
Deferred Taxes:	(184)
Prior Year Taxes	(176)
Total Taxes	3,213	3,183
Outside U.S [Member]
Income (loss) before taxes on income:
Income (loss) before taxes on income	28,900	(7,067)
Taxes on income (tax benefit)
Deferred Taxes:	8,095
Prior Year Taxes
Total Taxes	$ 8,095

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Accounting Policies, by Policy (Policies)

12 Months Ended

Dec. 31, 2025

Significant Accounting Policies [Abstract]

General

General

Oramed Pharmaceuticals Inc. (collectively with its subsidiaries, the “Company,” unless the context indicates otherwise), a Delaware corporation, was incorporated on April 12, 2002.

On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the “Subsidiary”), which is engaged in research and development.

Joint venture with HTIT

Investment in Alpha Tau Medical Ltd.

Basis of presentation

Basis of presentation

The consolidated financial statements included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”).

Use of estimates in the preparation of financial statements

Use of estimates in the preparation of financial statements

As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to the investments at fair value (for further details, see note 4).

Functional currency

Functional currency

Repurchase and retirement of common stock

Repurchase and retirement of common stock

The Company debited the common stock account by the par value of the shares retired and allocated the excess of the repurchase price over the par value of the shares to additional paid in capital.

Principles of consolidation

Principles of consolidation

The consolidated financial statements include the accounts of the Company and its subsidiaries. All inter-company transactions and balances have been eliminated in consolidation.

Cash equivalents

Cash equivalents

Fair value measurement

Fair value measurement:

	Level 1:	Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

	Level 2:	Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

	Level 3:	Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:

	December 31, 2025
	Level 1		Level 2		Level 3		Fair Value
Assets:
Marketable Securities
DNA		540		-		-		540
Entera		227		-		-		227
Nano		8,371		-		-		8,371
Pelthos		4,650		-		-		4,650
Investment in Alpha Tau’s shares (see note 8)		71,623		-		-		71,623
Loan to an equity method investee (see note 6)		-		-		553		553
Warrants Note B (see note 4)		-		-		850		850
Tranche A Note (see note 4)		-		-		23,063		23,063
Tranche B Note (see note 4)		-		-		11,473		11,473
Royalty Purchase Agreement (see note 4)		-		-		2,209		2,209
Profit Sharing Loan Agreement (see note 4 (e))		-		-		1,890		1,890
Loan agreement measured in fair value (see note 7)		-		-		27,943		27,943
Investment in Alpha Tau’s warrants (see note 8)		-		-		6,242		6,242
Convertible note (see note 9)		-		-		4,636		4,636
	$	85,411	$	-	$	78,859	$	164,270

	December 31, 2024
	Level 1		Level 2		Level 3		Fair Value
Assets:
Marketable Securities
DNA		424		-		-		424
Entera		248		-		-		248
Scilex		2,769		-		-		2,769
Subsequent Penny Warrants (see note 4)		-		2,772		-		2,772
Warrants Note B (see note 4)		-		-		548		548
Tranche A Note (see note 4)		-		-		13,714		13,714
Tranche B Note (see note 4)		-		-		15,798		15,798
Royalty Purchase Agreement (see note 4)		-		-		1,976		1,976
Profit Sharing Loan Agreement (see note 4)		-		-		1,367		1,367
	$	3,441	$	2,772	$	33,403	$	39,616

The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.

Marketable securities

Marketable securities

Other non-marketable equity securities

Other non-marketable equity securities

Investments measured at fair value

Investments measured at fair value

Changes in the fair value are recorded under financial income (expenses), net.

Concentration of credit risks

Concentration of credit risks

Income taxes

Income taxes

Deferred taxes

Uncertainty in income tax

Revenue recognition

Revenue recognition

HTIT

Other income

Other income

In addition, the Company recorded an income of $549 related to the straight-line recognition of the Alpha Tau Warrants under “Other income, net”. For further details, see Note 8.

Research and development

Research and development

Stock-based compensation

Stock-based compensation

If a market condition associated with PSUs is satisfied earlier than originally expected, any remaining unrecognized compensation cost related to such awards is recognized immediately.

The Company elects to account for forfeitures as they occur.

Income (loss) per share of common stock

Income (loss) per share of common stock

Investment in Alpha Tau

Investment in Alpha Tau

Summarized financial information for Alpha Tau, as determined in accordance with Rule 8-03(b)(3) of Regulation S-X is included in note 8.

Leases

Leases

The Company elected the practical expedient to not separate lease and non-lease components for all of its leases.

Lease terms will include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease.

New accounting pronouncements

New accounting pronouncements

Recently adopted accounting pronouncements

Recently issued accounting pronouncements, not yet adopted

Commitments - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities [Abstract]
Operating right-of-use assets	$ 750	$ 414
Operating lease liabilities, current	285	216
Operating lease liabilities long-term	540	156
Total operating lease liabilities	$ 825	$ 372
Weighted Average of Remaining Lease Term
Operating leases	3 years 9 months 3 days	1 year 9 months 18 days
Weighted Average Discount Rate
Operating leases percentage	6.30%	3.52%

Investments, at Fair Value - Schedule of Fair Value Breakdown (Details) $ in Thousands	Dec. 31, 2025 USD ($)
Schedule of Fair Value Breakdown [Line Items]
Fair Value	$ 37,595
Notes [Member]
Schedule of Fair Value Breakdown [Line Items]
Fair Value	34,536
Warrants [Member]
Schedule of Fair Value Breakdown [Line Items]
Fair Value	850
Royalty Purchase Agreement payment [Member]
Schedule of Fair Value Breakdown [Line Items]
Fair Value	2,209
Tranche A Note [Member]
Schedule of Fair Value Breakdown [Line Items]
Amount
Fair Value	23,063
Tranche A Note [Member] \| Notes [Member]
Schedule of Fair Value Breakdown [Line Items]
Amount	7,675
Accrued Interest	17,153
Fair Value	23,063
Tranche A Note [Member] \| Warrants [Member]
Schedule of Fair Value Breakdown [Line Items]
Amount
Accrued Interest
Fair Value
Tranche A Note [Member] \| Royalty Purchase Agreement payment [Member]
Schedule of Fair Value Breakdown [Line Items]
Amount
Accrued Interest
Fair Value
Tranche B Note [Member]
Schedule of Fair Value Breakdown [Line Items]
Accrued Interest
Fair Value	14,532
Tranche B Note [Member] \| Notes [Member]
Schedule of Fair Value Breakdown [Line Items]
Amount	15,125
Accrued Interest	341
Fair Value	11,473
Tranche B Note [Member] \| Warrants [Member]
Schedule of Fair Value Breakdown [Line Items]
Amount	207,143
Accrued Interest
Fair Value	850
Tranche B Note [Member] \| Royalty Purchase Agreement payment [Member]
Schedule of Fair Value Breakdown [Line Items]
Amount
Accrued Interest
Fair Value	$ 2,209

- Definition

Cost of the investment.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477439/946-210-55-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 19
-Subparagraph (3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19

+ Details

- Definition

Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.

+ References + Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Schedule of Accounts Payable and Accrued Expenses [Abstract]
Accounts payable	$ 443	$ 789
Payroll and related accruals	755	407
Income tax	3,286	3,204
Accrued liabilities – Legal Fee	1,084	402
Accrued liabilities – Other	633	338
Total	$ 6,201	$ 5,140

Taxes on Income - Schedule of Assuming all Income is Taxed at Regular Tax Rates Applicable to Companies in United States, and Actual Tax Expense (Parentheticals) (Details)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Schedule of Assuming all Income is Taxed at Regular Tax Rates Applicable to Companies in United States, and Actual Tax Expense [Abstract]
Statutory tax (benefit) expense, value	21.00%	21.00%

Commitments

12 Months Ended

Dec. 31, 2025

Commitments [Abstract]

COMMITMENTS

NOTE 13 - COMMITMENTS:

Medicox

On November 13, 2022, the Company entered the Medicox License Agreement with Medicox (the “Medicox License Agreement”).

The Medicox License Agreement grants Medicox an exclusive license to apply for regulatory approval and distribute ORMD-0801 in the Republic of Korea. The Medicox License Agreement is for ten years, but the parties have the right to terminate it with a 180 days notice.

Medicox will comply with agreed distribution targets, purchase ORMD-0801 at an agreed transfer price per capsule and will be responsible for obtaining a regulatory approval in the Republic of Korea. The Medicox License Agreement contains a fixed consideration of $2,000, which was received by the Company during the year ended December 31, 2022 and is presented under long-term deferred revenues, as well as variable consideration consisting of development milestone payments of up to $15,000 and sales-based royalties of up to 15% on gross sales.

Under ASC 606 ,Revenue from Contracts with Customers, the Company identified Medicox as a customer and the Medicox License Agreement as a contract with a customer.

The Company’s obligation to stand-ready and support Medicox will be recognized on a straight-line basis over the period the Company expects to provide support to Medicox. As of December 31, 2025, this support has not commenced, and no revenue was recognized from the Medicox License Agreement.

If Medicox proceeds with the regulatory approval process in the Republic of Korea, the Company expects most of the revenue to be recognized at a later stage, going forward. If Medicox chooses to terminate the agreement, the Company will accelerate revenue recognition and recognize it at such time.

Grants from the Israel Innovation Authority (“IIA”)

Under the terms of the Company’s funding from the IIA, royalties of 3% are payable on sales of products developed from a project so funded, up to a maximum amount equaling 100%-150% of the grants received (dollar linked) with the addition of interest at an annual rate based on SOFR.

All grants were received before the year ended August 31, 2020 and recorded as a reduction of research and development expenses at that time. At the time the grants were received, successful development of the related projects was not assured. The total amount that was received through December 31, 2025 was $2,213 ($2,570 including interest).

On February 18, 2025, the Company received approval from the IIA to transfer all of its IIA-funded technology to OraTech in accordance with the terms of the JV Agreement. This approval was granted upon the condition that the Company pays the aggregate IIA grant amount, plus accrued interest, less all royalties paid to date.

On February 27, 2025, the Company fulfilled its payment obligation by remitting $2,046 to the IIA, and as result the Company has no further obligations to the IIA. The amount of $1,987 was recognized in cost of revenue during the year ended December 31, 2025. The amount of $59 was recognized in previous periods.

Leases

On August 2, 2020, the Subsidiary entered into a lease agreement for its facilities in Israel. The lease agreement is for a period of 60 months commencing September 1, 2020. As security for its obligation under this lease agreement, the Company provided a bank guarantee in an amount equal to three monthly lease payments. For accounting purposes, the initial lease period was 60 months. During the year ended December 31, 2025, the Company exercised the extension option for a portion of its office space, extending the lease term until August 31, 2030.

In connection with the extension of the lease agreement, the Company remeasured the right-of-use (ROU) asset and corresponding lease liability in accordance with ASC 842. The updated balances reflect the revised lease term and related payment obligations through August 31, 2030.

On December 2, 2021, the Subsidiary entered into an addendum (the “Addendum”) to the current lease agreement for its facilities in Israel. The Addendum refers to the lease of an additional space of 264 square meters for a period of 60 months commencing February 1, 2022. The Subsidiary has the option to extend the period for another 60 months. For accounting purposes, the lease commenced on February 1, 2022 as the Subsidiary did not have access to the space until that date. For accounting purposes, the lease period is 60 months.

The total expenses related to leases were $238 for the year ended December 31, 2025, and $265 for the year ended December 31, 2024.

The Company has various operating leases for office space and vehicles that expire through 2028. Below is a summary of the Company’s operating right-of-use assets and operating lease liabilities as of December 31, 2025 and 2024:

	December 31, 2025			December 31, 2024
Operating right-of-use assets	$	750		$	414

Operating lease liabilities, current		285			216
Operating lease liabilities long-term		540			156
Total operating lease liabilities	$	825		$	372

Weighted Average of Remaining Lease Term
Operating leases		3.76			1.8

Weighted Average Discount Rate
Operating leases		6.3	%		3.52	%

Operating cash flows for operating lease for the years ended December 31, 2025 and 2024 were $292 and $264, respectively.

Lease payments for the Company’s right-of-use assets over the remaining lease periods as of December 31, 2025 are as follows:

	December 31, 2025

2026	$	332
2027		192
2028		163
2029		157
2030		104
Total undiscounted lease payments		948
Less: Interest*		(123	)
Present value of lease liabilities	$	825

*	Future lease payments were discounted by 3%-7% interest rate.

Clinical Research Organization Services Agreement

On September 23, 2024, the Subsidiary entered into a Clinical Research Organization Services Agreement with a third party, to retain it as a clinical research organization (“CRO”). The services covered by the agreement include strategic planning, expert consultation, data processing, regulatory, clerical, project management and other research and development services requested by the Company for the Phase 3 clinical trial. As consideration for its services, the Company will pay the CRO a total amount of $11,577 during the term of the engagement and based on achievement of certain milestones, of which $1,406 recognized in research and development expenses through December 31, 2025.

The Company modified its clinical trial protocol and overall trial approach. The proposed new protocol is significantly smaller in scope and will enroll fewer participants than the original trial design. As a result of these changes, the Company is currently reexamining the terms and scope of the CRO Services Agreement to align with the revised trial design. See additional information in note 21.

Ruby Sapphire II Investment

On December 29, 2025, the Company entered into agreement and committed to invest NIS 7,000 ($2,185) as a limited partner in Ruby Capital Investment Fund Sapphire II, Limited Partnership (“Ruby Sapphire II”), an Israeli private investment fund. The Company commitment may be drawn down over time in accordance with the fund’s partnership agreement, and the investment is subject to the risks inherent in private investment funds, including illiquidity and the potential loss of invested capital. See additional information in the subsequent events note.

Significant Accounting Policies - Schedule of Fair Value Measurements on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Marketable Securities
Marketable Securities	$ 164,270	$ 39,616
Level 1 [Member]
Marketable Securities
Marketable Securities	85,411	3,441
Level 2 [Member]
Marketable Securities
Marketable Securities		2,772
Level 3 [Member]
Marketable Securities
Marketable Securities	78,859	33,403
DNA [Member]
Marketable Securities
Marketable Securities	540	424
DNA [Member] \| Level 1 [Member]
Marketable Securities
Marketable Securities	540	424
DNA [Member] \| Level 2 [Member]
Marketable Securities
Marketable Securities
DNA [Member] \| Level 3 [Member]
Marketable Securities
Marketable Securities
Entera [Member]
Marketable Securities
Marketable Securities	227	248
Entera [Member] \| Level 1 [Member]
Marketable Securities
Marketable Securities	227	248
Entera [Member] \| Level 2 [Member]
Marketable Securities
Marketable Securities
Entera [Member] \| Level 3 [Member]
Marketable Securities
Marketable Securities
Nano [Member]
Marketable Securities
Marketable Securities	8,371
Nano [Member] \| Level 1 [Member]
Marketable Securities
Marketable Securities	8,371
Nano [Member] \| Level 2 [Member]
Marketable Securities
Marketable Securities
Nano [Member] \| Level 3 [Member]
Marketable Securities
Marketable Securities
Pelthos [Member]
Marketable Securities
Marketable Securities	4,650
Pelthos [Member] \| Level 1 [Member]
Marketable Securities
Marketable Securities	4,650
Pelthos [Member] \| Level 2 [Member]
Marketable Securities
Marketable Securities
Pelthos [Member] \| Level 3 [Member]
Marketable Securities
Marketable Securities
Investment in Alpha Tau's shares [Member]
Marketable Securities
Marketable Securities	71,623
Investment in Alpha Tau's shares [Member] \| Level 1 [Member]
Marketable Securities
Marketable Securities	71,623
Investment in Alpha Tau's shares [Member] \| Level 2 [Member]
Marketable Securities
Marketable Securities
Investment in Alpha Tau's shares [Member] \| Level 3 [Member]
Marketable Securities
Marketable Securities
Loan to an equity method investee [Member]
Marketable Securities
Marketable Securities	553
Loan to an equity method investee [Member] \| Level 1 [Member]
Marketable Securities
Marketable Securities
Loan to an equity method investee [Member] \| Level 2 [Member]
Marketable Securities
Marketable Securities
Loan to an equity method investee [Member] \| Level 3 [Member]
Marketable Securities
Marketable Securities	553
Warrants Note B [Member]
Marketable Securities
Marketable Securities	850	548
Warrants Note B [Member] \| Level 1 [Member]
Marketable Securities
Marketable Securities
Warrants Note B [Member] \| Level 2 [Member]
Marketable Securities
Marketable Securities
Warrants Note B [Member] \| Level 3 [Member]
Marketable Securities
Marketable Securities	850	548
Tranche A Note [Member]]
Marketable Securities
Marketable Securities	23,063	13,714
Tranche A Note [Member]] \| Level 1 [Member]
Marketable Securities
Marketable Securities
Tranche A Note [Member]] \| Level 2 [Member]
Marketable Securities
Marketable Securities
Tranche A Note [Member]] \| Level 3 [Member]
Marketable Securities
Marketable Securities	23,063	13,714
Tranche B Note [Member]
Marketable Securities
Marketable Securities	11,473	15,798
Tranche B Note [Member] \| Level 1 [Member]
Marketable Securities
Marketable Securities
Tranche B Note [Member] \| Level 2 [Member]
Marketable Securities
Marketable Securities
Tranche B Note [Member] \| Level 3 [Member]
Marketable Securities
Marketable Securities	11,473	15,798
Royalty Purchase Agreement [Member]
Marketable Securities
Marketable Securities	2,209	1,976
Royalty Purchase Agreement [Member] \| Level 1 [Member]
Marketable Securities
Marketable Securities
Royalty Purchase Agreement [Member] \| Level 2 [Member]
Marketable Securities
Marketable Securities
Royalty Purchase Agreement [Member] \| Level 3 [Member]
Marketable Securities
Marketable Securities	2,209	1,976
Profit Sharing Loan Agreement [Member]
Marketable Securities
Marketable Securities	1,890	1,367
Profit Sharing Loan Agreement [Member] \| Level 1 [Member]
Marketable Securities
Marketable Securities
Profit Sharing Loan Agreement [Member] \| Level 2 [Member]
Marketable Securities
Marketable Securities
Profit Sharing Loan Agreement [Member] \| Level 3 [Member]
Marketable Securities
Marketable Securities	1,890	1,367
Loan agreement measured in fair value [Member]
Marketable Securities
Marketable Securities	27,943
Loan agreement measured in fair value [Member] \| Level 1 [Member]
Marketable Securities
Marketable Securities
Loan agreement measured in fair value [Member] \| Level 2 [Member]
Marketable Securities
Marketable Securities
Loan agreement measured in fair value [Member] \| Level 3 [Member]
Marketable Securities
Marketable Securities	27,943
Investment in Alpha Tau's warrants [Member]
Marketable Securities
Marketable Securities	6,242
Investment in Alpha Tau's warrants [Member] \| Level 1 [Member]
Marketable Securities
Marketable Securities
Investment in Alpha Tau's warrants [Member] \| Level 2 [Member]
Marketable Securities
Marketable Securities
Investment in Alpha Tau's warrants [Member] \| Level 3 [Member]
Marketable Securities
Marketable Securities	6,242
Convertible note [Member]
Marketable Securities
Marketable Securities	4,636
Convertible note [Member] \| Level 1 [Member]
Marketable Securities
Marketable Securities
Convertible note [Member] \| Level 2 [Member]
Marketable Securities
Marketable Securities
Convertible note [Member] \| Level 3 [Member]
Marketable Securities
Marketable Securities	$ 4,636
Scilex [Member]
Marketable Securities
Marketable Securities		2,769
Scilex [Member] \| Level 1 [Member]
Marketable Securities
Marketable Securities		2,769
Scilex [Member] \| Level 2 [Member]
Marketable Securities
Marketable Securities
Scilex [Member] \| Level 3 [Member]
Marketable Securities
Marketable Securities
Subsequent Penny Warrants [Member]
Marketable Securities
Marketable Securities		2,772
Subsequent Penny Warrants [Member] \| Level 1 [Member]
Marketable Securities
Marketable Securities
Subsequent Penny Warrants [Member] \| Level 2 [Member]
Marketable Securities
Marketable Securities		2,772
Subsequent Penny Warrants [Member] \| Level 3 [Member]
Marketable Securities
Marketable Securities